<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006346" GROUP_ID="SCHIZ" ID="666506090514474397" MERGED_FROM="" MODIFIED="2012-07-25 14:58:51 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-25 14:57:13 +0100" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-07-25 14:57:13 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Morita therapy for schizophrenia</TITLE>
<CONTACT>
<PERSON ID="D969CBDD82E26AA2001A75539D8AAB45" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Yanling</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>He</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>heyl2001@yahoo.com.cn</EMAIL_1>
<EMAIL_2>heyl2001@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>Shanghai Mental Health Center, Shanghai Jiaotong University</ORGANISATION>
<ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Shanghai</CITY>
<ZIP>200030</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>(86 21)64387250 ext. 3068</PHONE_1>
<PHONE_2/>
<FAX_1>(86 21)64387986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-07-25 14:39:09 +0100" MODIFIED_BY="Claire Irving">
<PERSON ID="D969CBDD82E26AA2001A75539D8AAB45" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Yanling</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>He</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>heyl2001@yahoo.com.cn</EMAIL_1>
<EMAIL_2>heyl2001@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>Shanghai Mental Health Center, Shanghai Jiaotong University</ORGANISATION>
<ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Shanghai</CITY>
<ZIP>200030</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>(86 21)64387250 ext. 3068</PHONE_1>
<PHONE_2/>
<FAX_1>(86 21)64387986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7E028C0382E26AA200C1C7C465D3B6B4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Chunbo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Li</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>chunbo_li@yahoo.com</EMAIL_1>
<EMAIL_2>chunbo_li@163.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biological Psychiatry</DEPARTMENT>
<ORGANISATION>Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine</ORGANISATION>
<ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Shanghai</CITY>
<ZIP>200030</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 21 64387250 ext 3243</PHONE_1>
<PHONE_2/>
<FAX_1>+86 21 64387986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-07-25 14:57:13 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="1" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-07-25 14:51:56 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-05 14:05:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 10 studies added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-07-25 14:51:56 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-25 14:51:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 14:35:50 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="15" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-02-15 15:14:28 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="18" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 15:14:28 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="24" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-07-20 09:38:23 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-07-20 09:38:23 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-07-20 09:38:23 +0100" MODIFIED_BY="[Empty name]">
<NAME>Tongji University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-07-20 09:38:23 +0100" MODIFIED_BY="[Empty name]">
<NAME>Shanghai Mental Health Center</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-07-20 09:37:32 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-07-18 14:36:49 +0100" MODIFIED_BY="[Empty name]">
<NAME>Davis Family Foundation</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-07-20 09:37:32 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Basic Research Program of China (973 Program, 2007CB512306)</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION>
<P>Chunbo Li is also partly supported from 973 Program, 2007CB512306</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-07-25 14:56:43 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-27 11:49:12 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-25 17:54:02 +0100" MODIFIED_BY="[Empty name]">Morita therapy for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-27 11:49:12 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a long-term, chronic illness with a high disability rate and disease burden. Treatment for schizophrenia should focus on the wider social aspects of living in the community in addition to medicating the immediate symptoms of this long-term illness. Reliance on medication alone is insufficient, especially for patients with an illness which is often very debilitating. There are several kinds of intervention strategies available, often involving both the individual sufferer and the wider family unit; Morita therapy being one of these.</P>
<P>Morita therapy is a systematic psychotherapy based on Eastern psychology. The aim of this type of therapy is to alleviate the anxiety of sufferers and eliminate neurotic symptoms by encouraging the patient to accept anxiety as a natural state, whilst at the same time engaging them in constructive behaviours via four phases. To date the efficacy of Morita therapy for schizophrenia has not been verified systematically. In this review we analysed the effects of Morita therapy in hospital settings for people with schizophrenia or schizophrenia-like conditions.</P>
<P>We were only able to include 12 studies, which varied in terms of the number of treatment phases used, and duration of treatment. Six studies were not blinded and four were inadequately randomised. Results indicate Morita therapy may have some early positive effects, but there is no data to assess whether this can be sustained in the long term. This review highlights the need for better-designed studies to assess the efficacy of this therapy in the treatment of schizophrenia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-07-25 14:54:13 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-09-18 18:15:54 +0100" MODIFIED_BY="[Empty name]">
<P>Morita therapy was founded in 1919 by Shoma Morita (1874-1938). The therapy involves a behavioural structured program to encourage an outward perspective on life and increased social functioning.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-09-18 18:14:53 +0100" MODIFIED_BY="[Empty name]">
<P> To evaluate the effects of Morita therapy for schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-07-25 14:53:23 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Groups Trials Register, the Chongqing VIP Database, and the Wanfang Database (July 2008) for all relevant references. The first author of each included study was also contacted.</P>
<P>We updated this search (July 2012) and added the results to the awaiting classification section of the review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-09-18 18:14:53 +0100" MODIFIED_BY="[Empty name]">
<P> We included all randomised clinical trials comparing Morita therapy with any other treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-10-27 11:17:14 +0000" MODIFIED_BY="[Empty name]">
<P>We reliably selected studies and extracted data. For homogenous dichotomous data we calculated random-effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-27 11:27:16 +0000" MODIFIED_BY="[Empty name]">
<P>We found 12 small, studies of medium-poor quality (total n=1123). The standard care versus Morita therapy comparison (total n=761 people) had very low attrition (&lt;2%, 10 RCTs, RR 1.01 CI 0.4 to 2.8). Mental state did tend to improve with Morita therapy (n=76, 1 RCT, number of &gt;25-30% decline in BPRS, RR 0.36 CI 0.1 to 0.9, NNT 5 CI 4 to 25). For negative symptoms data were inconsistent, with data from four short-term trials favouring Morita therapy (n=323, WMD average endpoint SANS -12.94 CI -21.6 to -4.3), but heterogeneity was considerable (I<SUP>2</SUP> =97%). In medium-term studies, negative symptoms were favoured by Morita therapy (n=44, 1 RCT, RR &gt;25% decline SANS 0.25 CI 0.1 to 0.8, NNT 3 CI 2 to 8). Morita therapy plus standard treatment did significantly improve the activities of daily living compared with standard treatment alone (n=104, 1 RCT, WMD -4.1 average endpoint ADL CI -7.7 to -0.6). Compared with a rehabilitation programme Morita therapy did not promote attrition (n=302, 2 RCTs, RR leaving early 1.00 CI 0.5 to 2.1). In two very similar studies Morita therapy showed better effect on mental state with lower BPRS score (n=278, 2 RCTs, WMD average endpoint BPRS -6.95 CI -9.3 to -4.6, I<SUP>2</SUP> =0%), insight score (n=278, 2 RCTs, WMD average endpoint clinical judgement score -1.11 CI -1.3 to -0.9, I<SUP>2</SUP> = 0%) and social functioning (n=278, WMD average endpoint IPROS -18.14 CI -21.3 to -15.0, I<SUP>2</SUP> =0%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-25 14:54:13 +0100" MODIFIED_BY="[Empty name]">
<P>Morita therapy for schizophrenia remains an experimental intervention. New trials are justified and specific plans for the design of future studies are outlined.</P>
<P>[Note: the 10 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-07-25 14:56:43 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-27 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-10-27 11:46:20 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a long-term, chronic illness with high disability rates and disease burden. Interventions for the purpose of reintegration into society are even more important than acute intervention. Maintenance on medication alone has been shown to be inadequate, especially as regards social functioning. Within the context of long hospital stays for psychotic patients, mainly people with schizophrenia, inpatient rehabilitation takes an important role alongside acute intervention. Morita therapy is one treatment used in some Asian countries for people with schizophrenia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-10-27 11:52:43 +0000" MODIFIED_BY="[Empty name]">
<P>Morita therapy was founded in 1919 by Shoma Morita (1874-1938) and is a systematic psychotherapy based on Eastern psychology. This therapy approaches people's problems from the collective perspective rather than that of the individual. Its fundamental premise is that Asians are more of a collectivist culture, rather than an individual culture (<A HREF="http://en.wikipedia.org/wiki/Asian_psychology">http://en.wikipedia.org/wiki/Asian_psychology</A>). It is used mainly in Japan and China and there are 66 Morita therapy institutes or units in China either for inpatient/outpatient/self help groups or for research (<LINK REF="REF-Wen-2001" TYPE="REFERENCE">Wen 2001</LINK>).</P>
<P>The theory and treatment methods of this therapy have been modified since its founding. Its original application in anxiety disorders has been expanded for use in schizophrenia and the treatment duration is now shortened to six weeks, although the longer four phases are still used (<LINK REF="REF-Lu-1995" TYPE="REFERENCE">Lu 1995</LINK>). Further variations in the treatment methods have been developed. The efficacy of Morita therapy for patients with neurosis has been reported (<LINK REF="REF-Suzuki-1989" TYPE="REFERENCE">Suzuki 1989</LINK>) although these positive results were not without controversy (<LINK REF="REF-Reynolds-1980" TYPE="REFERENCE">Reynolds 1980</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2008-10-27 11:57:37 +0000" MODIFIED_BY="[Empty name]">
<P>Morita therapy attempts to lead patients from preoccupation with somatic symptoms and tries to eliminate neurotic symptoms by accepting anxiety as natural whilst engaging in constructive behaviours via four phases:<BR/>
<BR/>1. Bed rest in isolation for seven days, during which patients stay in their room all day with activity restricted to meals, a morning wash, and going to the toilet, and no access to reading, radio, TV or any form of entertainment.</P>
<P>2. Light work for four to seven days. During this the patient: a) initiates, under therapist's guidance, graded activity and work needed in daily living at the hospital; b) writes in a diary what he or she did on a daily basis and every day submits this to the therapist who reads it, writes comments, and returns it to the patient (diary guidance); c) has interviews two to three times a week with the therapist who does not regard symptoms as foremost and focuses on daily activities (strategic inattention to symptoms, contingency management).</P>
<P>3. Work for one to two months with gradual engagement in activities such as gardening, caring for animals and cooking and eventually doing these together with other patients.</P>
<P>4. Preparation for normal daily living over one to four weeks which may include commuting to work or school from the ward (<LINK REF="REF-Takeda-1964" TYPE="REFERENCE">Takeda 1964</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-27 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Morita therapy for people with schizophrenia is a relatively recent practice (<LINK REF="REF-Lu-1995" TYPE="REFERENCE">Lu 1995</LINK>). This originated in Japan and then gained popularity in Chinain the mid-1990s (<LINK REF="REF-Wen-2001" TYPE="REFERENCE">Wen 2001</LINK>). This review updates our last Cochrane review on this topic (<LINK REF="REF-He-2007" TYPE="REFERENCE">He 2007</LINK>) and we know of no other systematic reviews focusing on this increasingly prevalent approach.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-09-18 18:14:53 +0100" MODIFIED_BY="[Empty name]">
<P> To evaluate the effects, feasibility and safety of Morita therapy for schizophrenia and schizophrenia-like psychoses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-05 14:02:43 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-27 13:34:28 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-27 12:27:02 +0000" MODIFIED_BY="[Empty name]">
<P>All relevant randomised control trials (RCTs). Quasi-randomised studies, such as those allocating by using alternate days of the week may have a high risk of bias. In the context of a substantial proportion of the studies described as 'randomised' but actually not real RCTs, these quasi-randomised studies might not be lower in quality than those studies without clear descriptions of how randomisation was undertaken. We included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see 'types of outcome measures') when we added these 'inadequately randomised' studies, then we included these in the final analysis. If there was a substantive difference, we only analysed randomised trials and described the results of the sensitivity analysis in the text. If a trial was described as double blind, but it was implied it had been randomised, we included these trials in a sensitivity analysis.</P>
<P>Randomised cross-over studies will be eligible but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-09-18 18:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with schizophrenia and schizophrenia-like disorders such as schizophreniform disorder, delusional disorder or schizoaffective disorder, diagnosed by any criteria. We excluded people with dementing illnesses, depression and primarily problems associated with substance misuse.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-27 13:22:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. Morita therapy + standard care: any kinds of Morita therapy. For this review we defined Morita therapy as any care practice defined as Morita by the carers and involving at least two of the four phases described as above (see Background). The reason for defining two of the four phases of the therapy is so that people can be discharged from the hospital at phase two or phase three, in accordance with the practice in Japan (<LINK REF="REF-Lu-1995" TYPE="REFERENCE">Lu 1995</LINK>).</P>
<P>If several kinds of Morita therapy were compared with one of the control methods, the different kinds of Morita therapy were pooled. For example, for dichotomous data, all treated with varying kinds of Morita therapy were considered as a single group. For continuous data, the mean scores from different types of Morita therapy were added.</P>
<P>2. Placebo or no additional therapy + standard care. For the purposes of this review we defined standard care as the treatment, social, physical or psychological or a combination, usually available to people with schizophrenia either in inpatient or outpatient settings.</P>
<P>3. Other psychological interventions + standard care. For the purposes of this review we classified 'other psychological interventions' into four distinct groups and did not combine the results of different classes of psychological treatments:</P>
<P>3.1 Psychodynamic psychotherapy/Psychoanalysis<BR/>We defined psychodynamic psychotherapy as regular individual therapy sessions with a trained psychotherapist, or a therapist under supervision. Therapy sessions were to be based on a psychodynamic or psychoanalytic model. Sessions could rely on a variety of strategies, including explorative insight-oriented, supportive or directive activity, applied flexibly. However, therapists should use a less strict technique than in psychoanalysis. To be considered well-defined psychodynamic psychotherapy, trialists needed to include working with transference. Psychoanalysis was defined as regular individual sessions, of a minimum duration of 30 minutes, three to five times a week, with a trained psychoanalyst with a minimum treatment duration of one year. Analysts were required to adhere to a strict definition of psychoanalytic technique. To be considered well-defined psychoanalysis, trialists needed to report working at the infantile sexual relations level of psychoanalytic theory.</P>
<P>3.2 Cognitive behavioural therapy<BR/>The label cognitive behavioural therapy (CBT) has been applied to a variety of interventions, and accordingly is difficult to provide a single unambiguous definition. Recognising this, we constructed criteria that were felt to be both workable and to capture the elements of good practice in CBT (<LINK REF="REF-Jones-2004" TYPE="REFERENCE">Jones 2004</LINK>).</P>
<P>In order to be classified as 'well-defined' the intervention must clearly demonstrate the following components:<BR/>i. the intervention involves the recipient establishing links between their thoughts, feelings and actions with respect to the target symptom;<BR/>ii. the intervention involves the correction of the person's misperceptions, irrational beliefs and reasoning biases related to the target symptom; and<BR/>iii. the intervention should involve either or both of the following: i. the recipient monitoring his or her own thoughts, feelings and behaviours with respect to the target symptom; and ii. the promotion of alternative ways of coping with the target symptom.</P>
<P>In addition, all therapies that do not meet these criteria (or that provide insufficient information) but are labelled as 'CBT' or 'Cognitive Therapy' were included as 'less well-defined' CBT. We conducted a sensitivity analysis on the primary outcomes of this review (see types of outcomes) in order to investigate if this hierarchy of definition made any difference.</P>
<P>3.3 Supportive<BR/>We have used the phrase 'supportive therapy and supportive care' to indicate a wider variety of interventions than supportive psychotherapy alone (<LINK REF="REF-Buckley-2007" TYPE="REFERENCE">Buckley 2007</LINK>). These interventions are provided by a single person with the main purpose of maintaining current functioning or assisting pre-existing coping abilities in people who have a diagnosis of schizophrenia or schizophrenia-like illnesses. The therapies can be aimed at individuals or groups. If the content of the therapy is not sufficiently clear after reading a clinical study, then we included any therapy that had supportive or support in its title. We have included advocacy as a form of supportive care. Advocacy is a narrower intervention than others included in the review, but it nevertheless fits our definition as it assists people with their communication and interaction with mental health workers.</P>
<P>We have excluded some therapies or schemes as they involve a team approach rather than an individual worker, or because they are designed to alter a person's environment, rather than to help the person cope with their environment. These include family placement (<LINK REF="REF-Pharoah-2006" TYPE="REFERENCE">Pharoah 2006</LINK>),<B> </B>supported employment and supported accommodation (<LINK REF="REF-Chilvers-2006" TYPE="REFERENCE">Chilvers 2006</LINK>). An exception is the interventions that clearly involve practitioners whose main purpose is to help a client cope with their current situation, rather than alter the situation to make it easier for the client.</P>
<P>We have also excluded counselling (unlike the meta-analysis from the National Institute of Clinical Excellence on supportive therapy) (<LINK REF="REF-NICE-2003" TYPE="REFERENCE">NICE 2003</LINK>). The main purpose of counselling is to give an opportunity for a client to explore, discover and clarify ways of living (<LINK REF="REF-DoH-2001" TYPE="REFERENCE">DoH 2001</LINK>). Counseling employs a wide variety of techniques, and the purpose may be to facilitate a change in someone's life rather than to maintain the current situation. As counselling has such a broad scope, an exception will be to include a clinical trial if there is a clear indication that the main purpose of counselling is to provide support rather than facilitate change or give an opportunity to explore personal issues.</P>
<P>3.4 Family therapy<BR/>We defined family therapy as a psychosocial intervention / education which involves not only the patient, but also their family members. It can be an individual family or family groups (<LINK REF="REF-Pharoah-2006" TYPE="REFERENCE">Pharoah 2006</LINK>).</P>
<P>4. Rehabilitation + standard care. For the purpose of this review, we included occupational therapy, social skills training, psycho-education (<LINK REF="REF-Pekkala-2002" TYPE="REFERENCE">Pekkala 2002</LINK>), compliance therapy (<LINK REF="REF-McIntosh-2006" TYPE="REFERENCE">McIntosh 2006</LINK>), problem-solving and entertainment therapy as rehabilitation for schizophrenia patients with no restriction to an in hospital context / environment. If the content of the therapy is not sufficiently clear after reading a clinical study, then we will include any intervention that has rehabilitation in its title.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-27 13:34:28 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-09-18 18:14:53 +0100" MODIFIED_BY="[Empty name]">
<P> Global state - relapse - short term</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-27 13:34:28 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide and natural causes</P>
<P>2. Global state<BR/>2.1 Relapse - beyond short term<BR/>2.2 No clinically important change in global state (as defined by individual studies)<BR/>2.3 Average endpoint global state score<BR/>2.4 Average change in global state scores</P>
<P>3. Service outcomes<BR/>3.1 Hospitalisation<BR/>3.2 Time to hospitalisation</P>
<P>4. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>4.1 No clinically important change in general mental state<BR/>4.2 Average endpoint general mental state score<BR/>4.3 Average change in general mental state scores<BR/>4.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia, depression, mania)<BR/>4.5 Average endpoint specific symptom score<BR/>4.6 Average change in specific symptom scores</P>
<P>5. General functioning<BR/>5.1 No clinically important change in general functioning<BR/>5.2 Average endpoint general functioning score<BR/>5.3 Average change in general functioning scores<BR/>5.4 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>5.5 Average endpoint specific aspects of functioning, such as social or life skills<BR/>5.6 Average change in specific aspects of functioning, such as social or life skills</P>
<P>6. Behaviour<BR/>6.1 No clinically important change in general behaviour<BR/>6.2 Average endpoint general behaviour score<BR/>6.3 Average change in general behaviour scores<BR/>6.4 No clinically important change in specific aspects of behaviour<BR/>6.5 Average endpoint specific aspects of behaviour<BR/>6.6 Average change in specific aspects of behaviour</P>
<P>7. Adverse effects<BR/>7.1 Clinically important general adverse effects<BR/>7.2 Average endpoint general adverse effect score<BR/>7.3 Average change in general adverse effect scores<BR/>7.4 Clinically important specific adverse effects<BR/>7.5 Average endpoint specific adverse effects<BR/>7.6 Average change in specific adverse effects</P>
<P>8. Engagement with services</P>
<P>9. Satisfaction with treatment<BR/>9.1 Leaving the studies early<BR/>9.2 Recipient of care not satisfied with treatment<BR/>9.3 Recipient of care average satisfaction score<BR/>9.4 Recipient of care average change in satisfaction scores<BR/>9.5 Carer not satisfied with treatment<BR/>9.6 Carer average satisfaction score<BR/>9.7 Carer average change in satisfaction scores</P>
<P>10. Quality of life<BR/>10.1 No clinically important change in quality of life<BR/>10.2 Average endpoint quality of life score<BR/>10.3 Average change in quality of life scores<BR/>10.4 No clinically important change in specific aspects of quality of life<BR/>10.5 Average endpoint specific aspects of quality of life<BR/>10.6 Average change in specific aspects of quality of life</P>
<P>11. Economic outcomes<BR/>11.1 Direct costs<BR/>11.2 Indirect costs</P>
<P>12. Family outcome<BR/>12.1 Average score / change in family burden<BR/>12.2 Patient and family coping abilities<BR/>12.3 Understanding of the family member with schizophrenia<BR/>12.4 Family care and maltreatment of the person with schizophrenia<BR/>12.5 Expressed emotion<BR/>12.6 Quality of life, satisfaction with care for either recipients of care or their cares</P>
<P>13. Treatment compliance (taking medication)</P>
<P>We grouped outcomes as short term (up to 12 weeks), medium term (13 to 52 weeks) and long term (over 52 weeks).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-07-05 14:02:43 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-07-05 14:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Schizophrenia Group Trials Register (August 2006, July 2008, July 2012)</P>
<P>For details of the search phrase see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>2. Chongqing VIP Database (July 2008)</P>
<P>For details of search phrase see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>3. Wanfang Database (July 2008)</P>
<P>For details of search phrase see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-27 13:38:12 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference Searching</P>
<P>We inspected the references of all identified studies lists of all studies selected for full text inspection (see Methods below) for more trials.</P>
<P>2. Personal contact</P>
<P>We contacted the first author of each included study for information regarding unpublished trials.</P>
<P>[For references using Chinese characters in their title, because this program does not support inclusion of these characters, we have included graphic files with the references - <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>, <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>, <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>, <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>, <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>, <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>, <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>, <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK> - and a note in each reference directing to the relevant file.]</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-27 14:07:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-09-18 18:22:07 +0100" MODIFIED_BY="[Empty name]">
<P>Authors YH and CL independently inspected citations identified from the search. We identified potentially relevant reports and ordered full papers for reassessment. If doubts remained we acquired the full article for further inspection. We obtained full reports and independently reassessed these for inclusion. This process was repeated for the full papers. If it was impossible to resolve disagreements these studies were added to those awaiting assessment and the authors of the papers contacted for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-10-27 13:40:31 +0000" MODIFIED_BY="[Empty name]">
<P>1. Extraction</P>
<P>Authors YH and CL independently extracted data from included studies. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies were contacted for clarification.</P>
<P>2. Management</P>
<P>Data were extracted onto standard, simple forms.</P>
<P>3. Scale-derived data</P>
<P>We included continuous data from rating scales only if the measuring instrument has been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and the instrument is either a self-report or completed by an independent rater or relative (not the therapist).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-10-27 13:41:27 +0000" MODIFIED_BY="[Empty name]">
<P>Again working independently, YH and CL assessed risk of bias using the tool described in the Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-10-27 13:43:51 +0000" MODIFIED_BY="[Empty name]">
<P>1. Binary data</P>
<P>For binary outcomes we calculated a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (CI). For statistically significant result we calculated the number needed to treat/harm statistic (NNT/H), and its 95% confidence interval (CI) using Visual Rx (<A HREF="http://www.nntonline.net/">http://www.nntonline.net/</A>) taking account of the event rate in the control group.</P>
<P>2. Continuous data</P>
<P>2.1 Summary statistic</P>
<P>For continuous outcomes we estimated a fixed-effect weighted mean difference (WMD) between groups. We did not calculate effect size measures.</P>
<P>2.2 Endpoint versus change data</P>
<P>We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.</P>
<P>2.3 Skewed data</P>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aim to apply the following standards to all data before inclusion: (a) standard deviations and means are reported in the paper or obtainable from the authors; (b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. Skewed data from studies of less than 200 participants were entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-10-27 13:46:59 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials</P>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation co-efficient of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>If cluster studies has been appropriately analysed taking into account intraclass correlation co-efficient and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials</P>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups</P>
<P>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-10-27 13:50:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. Overall loss of credibility</P>
<P>At some degree of loss of follow up data must lose credibility. We are forced to make a judgment where this is for the trials likely to be included in this review. Should more than 40% of data be unaccounted for by 12 weeks or longer we did not reproduce these data or use them within analyses.</P>
<P>2. Binary</P>
<P>In the case where attrition for a binary outcome is between 0 and 40% and outcomes of these people are described, we included these data as reported. Where these data were not clearly described, we assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded.</P>
<P>3. Continuous</P>
<P>In the case where attrition for a continuous outcome is between 0 and 40% and completer-only data were reported, we have reproduced these.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-09-18 18:37:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity</P>
<P>We considered all included studies without any comparison to judge clinical heterogeneity.</P>
<P>2. Statistical</P>
<P>2.1 Visual inspection</P>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>2.2 Employing the I-squared statistic</P>
<P>This provided an estimate of the percentage of inconsistency thought to be due to chance. I-squared estimate greater than or equal to 50% was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-09-18 18:37:04 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-27 14:00:25 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias. For this reason we favour using a fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-10-27 14:05:40 +0000" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data are correctly extracted and entered and that we had made no unit of analysis errors. If the high levels of heterogeneity remained we did not undertake a meta-analysis at this point for if there is considerable variation in results, and particularly if there is inconsistency in the direction of effect, it may be misleading to quote an average value for the intervention effect. We would have wanted to explore heterogeneity. We pre-specify no characteristics of studies that may be associated with heterogeneity except quality of trial method. If no clear association could be shown by sorting studies by quality of methods a random-effects meta-analysis was performed. Should another characteristic of the studies be highlighted by the investigation of heterogeneity, perhaps some clinical heterogeneity not hitherto predicted but plausible causes of heterogeneity these post-hoc reasons will be discussed and the data analysed and presented. However, should the heterogeneity have been substantially unaffected by use of random-effects meta-analysis and no other reasons for heterogeneity be clear, the final data would have been presented without a meta-analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-27 14:07:25 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed the effect of our assumptions regarding those lost to follow-up in a sensitivity analysis for the primary outcome, but reported our data, assumption included, in the final analysis. In addition, we included trials in a sensitivity analysis if they were described as 'double blind' but only implied randomisation. If we found no substantive differences for the primary outcome these 'implied randomisation' studies were added to the overall results.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-07-25 14:56:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-07-25 14:56:43 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2008-10-27 14:07:54 +0000" MODIFIED_BY="[Empty name]">
<P>The initial search in the Cochrane Schizophrenia Groups Register (August 2006) resulted in 11 citations. Additional searching of Chinese databases found 11 citations published in short form without English title and abstract. A total of 20 citations are included for 11 included studies and five excluded trials. The update search of the Cochrane Schizophrenia Group's Register (July 2008) identified two additional studies (one included, another excluded). There were no studies from Japan.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-10-27 14:33:56 +0000" MODIFIED_BY="[Empty name]">
<P>We were able to include 12 studies with data from 1123 participants.</P>
<P>1. Setting<BR/>All studies were conducted in hospitals in the People's Republic of China between about 1994 and 2006.</P>
<P>2. Length of trials<BR/>Duration of Morita therapy varied, from six weeks (<LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>) to ten months (<LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>). According to our categories of duration of treatment, there were eight short-term studies (up to 12 weeks), and four medium-term trials (13 to 52 weeks). To date, we have identified no long-term studies.</P>
<P>3. Participants<BR/>All participants had a diagnosis of schizophrenia with only <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> not mentioning whether operational criteria were used. <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> included people with post-schizophrenic depression. Overall, the age of participants ranged from 15 to 65 years, but most were between 30 to 40 years. Most trials included both men and women, although three trials included only men (<LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>). <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> reported no information about the gender of patients. People in these trials had been ill for considerable periods of time, with a mean duration of illness between about five to 23 years. All participants were inpatients. In general, people who were excitable or had severe physical problems were not included in the studies.</P>
<P>4. Interventions<BR/>4.1 Intervention group<BR/>All participants received Morita therapy interventions plus standard care. Nine of the trials applied four phases of Morita therapy as described above in Types of intervention (<LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>, <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>). <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK> used two sessions of group therapy at the first phase instead of the more usual absolute bed rest. Three studies applied Morita therapy in three phases (<LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>). Finally, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> only reported modification of combining phase two and three together. Overall studies described the experimental intervention in such a way as to make inclusion in this review easy. The main aim of each of the Morita therapy interventions was to improve symptoms of schizophrenia and social functioning in order to facilitate return to normal everyday life. <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> and <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK> did construct their rehabilitation interventions to reflect the four phases of Morita therapy. Overall the rehabilitation interventions had much more of an emphasis on recreation rather than work, as is usually the case with Morita therapy.</P>
<P>4.2 Standard care<BR/>Standard care consisted of an antipsychotic prescribed at clinical dosages. <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, however, used a maintenance treatment in which the dosage of antipsychotics was one third that of usual treatment. <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, whose participants were classed as having post-schizophrenia depression, used antidepressant medication in addition to standard care.</P>
<P>4.5 Outcomes<BR/>We were able to extract data from some of the included studies on leaving the study early, mental state, social functioning, behaviour, adverse effects and quality of life. Outcomes relevant to people's mental state were reported as general mental states or as specific symptom clusters or both. We obtained data for 'no important improvement' from five studies (<LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>). This was, however, defined differently in each study. <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK> and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, stipulated that 'no important improvement' was a reduction of less than 25% BPRS scores. Similarly, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> defined 'no important improvement' was a reduction of less than 25% SANS scores and HAMD respectively, and <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK> defined it as a reduction of less than 30% BPRS total scores. <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> did not describe the criteria for no clinical important improvement on reduction of SAS scores. All 12 studies report data on the impact of Morita therapy on specific symptoms clusters such as depression or negative symptom scores. <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK> and <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, the only two studies evaluating the effects of Morita therapy against rehabilitation, specifically report insight scores. Seven studies report data from the Social Functioning Scale on such outcomes as social withdrawal, interpersonal behaviour, independence, recreational activities, pro-social activities and employment (<LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>). <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> included adverse events as an outcome measure. None of the other studies reported adverse events data. Scales from which data were reported are listed below.</P>
<P>4.5.1 Mental state<BR/>4.5.1.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>The BPRS is an 18-item scale measuring positive symptoms, general psychopathology and affective symptoms. The original scale has 16 items, but a revised 18-item scale is commonly used. Scores can range from 0-126. Each item is rated on a seven-point scale varying from 'not present' to 'extremely severe', with high scores indicating more severe symptoms. The BPRS was used by <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK>, <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>, and <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>.</P>
<P>4.5.1.2 Hamilton Rating Scale for Depression - HRSD (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>)<BR/>This is an interviewer-rated scale for measuring depression. It is used for quantifying the results of an interview and depends on the skill of the interviewer in eliciting the necessary information. It contains 17 variables measured on either a five-point or a three-point rating scale. The variables include: depressed mood, suicide, employment and loss of interest, retardation, agitation, gastro-intestinal symptoms, general somatic symptoms, hypochondriasis, loss of insight, and loss of weight. Higher scores indicate more severe depression. <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> reported data from this scale.</P>
<P>4.5.1.3 Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1983" TYPE="REFERENCE">Andreasen 1983</LINK>)<BR/>Used by <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>, and <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> to assess negative symptoms. This is a six-point scale, providing a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more negative symptoms.</P>
<P>4.5.2 Quality of life<BR/>4.5.2.1 Quality of Life Scale - QOLS (<LINK REF="REF-Song-1996" TYPE="REFERENCE">Song 1996</LINK>)<BR/>This scale contains 55 items, and has physical and psychological subscale scores and total scores. The total score and four sub-scale scores are calculated, with higher scores indicating better quality of life. <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> reported data from this scale.</P>
<P>4.5.3 Social functioning<BR/>4.5.3.1 Activities of Daily Living - ADL (<LINK REF="REF-Chen-1995" TYPE="REFERENCE">Chen 1995</LINK>)<BR/>The Chinese version of the Activities of Daily Living Scale (ADL, <LINK REF="REF-Chen-1995" TYPE="REFERENCE">Chen 1995</LINK>) is composed of Physical Self-Maintenance Scale (PSMS) and Instrumental Activities of Daily Living Scale (IADL). It has six items in PSMS and eight items in IADL. PSMS items include eating, bathing, dressing, grooming, transferring (e.g. moving from chair to bed and return), and using the toilet. IADL items include use of telephone, shopping, preparing a hot meal, doing house work, taking medication, managing financial matters, getting to places beyond walking distances, and doing laundry. Higher scores indicate more dependent and poor activities of daily living level.</P>
<P>4.5.3.2 Inpatient Psychiatric Rehabilitation Outcome Scale - IPROS (<LINK REF="REF-Li-1994" TYPE="REFERENCE">Li 1994</LINK>)<BR/>Inpatient Psychiatric Rehabilitation Outcome Scale (IPROS) has five subscales: performance in occupational therapy, daily activities, socialisation, personal hygiene, and level of interest in external events. Evaluators (physicians or nurses) observe patients for one week before coding items on a five-point scale. Higher scores indicate bad functional conditions.This scale was used by <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> and <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>.</P>
<P>4.5.3.3 Social Disability Screening Schedule - SDSS (<LINK REF="REF-Shen-1985" TYPE="REFERENCE">Shen 1985</LINK>)<BR/>Social Disability Screening Schedule (SDSS) has ten items. Each item is rated on a three-point scale varying from 'not present' to 'extremely severe'(0-2), with high scores indicating more severe symptoms. A total SDSS and item scores are calculated, with higher scores indicating much impairment. This scale was used by <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>.</P>
<P>4.5.4 Behaviour<BR/>4.5.4.1 Nurses' Observation Scale for Inpatients Evaluation - NOSIE (<LINK REF="REF-Honigfeld-1965" TYPE="REFERENCE">Honigfeld 1965</LINK>)<BR/>The NOSIE was developed as a behaviour-rating scale. This tool is sufficiently sensitive to measure therapeutic change in the patient with schizophrenic disorders. The scale is divided into the six categories of behaviour: social competence, social interest, personal neatness, irritability, psychosis, and motor retardation. These six categories include a total of 30 items that nurses rate using a 5-point response (0-4) scale that ranges from "never" to "always" (0=never present). Ratings are taken from behaviour over the previous three days or one week. The higher scores indicate poorer functioning. <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> and <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK> reported data from this scale.</P>
<P>4.5.5 Adverse events<BR/>4.5.5.1 Treatment-emergent signs and symptoms - TESS (<LINK REF="REF-NIMH-1985" TYPE="REFERENCE">NIMH 1985</LINK>).<BR/>This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. A low score indicates low levels of adverse effects. <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> reported data for this outcome.</P>
<P>4.5.6 Insight<BR/>Insight was measured using clinicians' judgement on patients' recognition of their illness and need for care (<LINK REF="REF-McEvoy-1989" TYPE="REFERENCE">McEvoy 1989</LINK>). The scale was validated against ratings from a semi-structured interview and against assessments of patients' compliance with medication. A low score indicates low levels of insight for the illness. <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> reported data for this outcome.</P>
<P>4.6 Unusable data<BR/>Many studies presented findings in aggregated statistical form or by inexact p values. These data could not be included. Some more data were lost because studies failed to report the outcomes of the control group (<LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>). One trial just reported cluster scores and not total scores of the scales they employed (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>). Such cluster scores are less likely to be validated than total scores and we did not report them.</P>
<P>4.7 Missing outcomes<BR/>We found no data on relapse, general clinical impression (primary outcome) and economic outcomes. None of these important outcomes were addressed by the trials that we included in this review. In addition, on reading the studies it became clear that a primary focus was social functioning in terms of reintegration back into society, although outcomes on readiness to resume normal life were not available. No follow-up data were reported for this package of care once treatments had ceased.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-07-25 14:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies</P>
<P>We excluded six studies. Three were not clinical controlled trials, one did not report on allocation, one was not Morita therapy and one paper was a review, rather than a trial.</P>
<P>2. Awaiting assessment<BR/>Ten studies await assessment.</P>
<P>3. Ongoing studies<BR/>We are not aware of any ongoing studies.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-27 15:18:56 +0000" MODIFIED_BY="[Empty name]">
<P>Because the quality of reporting of randomisation is not good, blinding is probably attempted but not tested, incomplete outcome data was not well addressed and loss to follow-up not well described, we think these trials to be of medium to poor quality. As a result it is likely that any findings will be biased in favour of the experimental group (Morita therapy) and that this bias may be up to a 40% overestimate of the effect (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>).</P>
<ALLOCATION MODIFIED="2008-09-18 18:26:30 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials were described as 'randomised'. Four studies, however, allocated the intervention by quasi-random methods. <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> allocated by registration number (odd or even). <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> randomly selected the patients from wards, and then equally divided these people into two groups. The paper did not report exactly how this equal division was achieved. <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> randomly selected patients from five wards; each ward recruited 20 patients, and then equally divided these people into two groups. Demographic data suggests that this process did result in evenly balanced groups implying that this study was indeed randomised. However, results from this study must be viewed with caution. <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>, <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> employed a quasi-random method of allocation it is possible that they were unacceptably open to the introduction of bias at the point of allocation. Data from these trials are included as the demographic variables are reported as being evenly distributed at allocation and we think they are likely to have been allocated treatments at random.</P>
<P>No study described concealment of allocation so doubt must remain about the introduction of bias and therefore we could not rate any study as good quality and all must have a moderate to high risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-09-18 18:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies reported that no form of blinding was used (<LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK>) and another two did not mention blinding (<LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>). Six studies attempted to ensure that raters were blind for part or the entire recording of outcome (<LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK>, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK>, <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>). No study tested the integrity of this blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-09-18 18:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>There were no direct descriptions of incomplete outcome data, and we were forced to judge loss to outcome from Results tables. Overall, reasons for withdrawal from studies are clearly reported in only three studies (<LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-09-18 18:37:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> reported data from only those who completed the study. We are unclear why this pattern of reporting was undertaken.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-27 14:50:26 +0000" MODIFIED_BY="[Empty name]">
<P>1. COMPARISON 1. Morita THERAPY + STANDARD versus STANDARD CARE<BR/>This comparison includes ten studies (total n=761 people).</P>
<P>1.1 Leaving the study early<BR/>All ten studies reported, directly or indirectly, study attrition by the end of treatment. Attrition rates were low with (&lt; 2%) leaving, and we found no difference between groups (n=761, 10 RCTs, RR 1.01 CI 0.4 to 2.8). Only three studies reported specific reasons for leaving the study early (<LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> - short term, <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK> - medium term). There were no significant differences between groups.</P>
<P>1.2 Mental state<BR/>BPRS data from <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK> and <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK> defined improvement as a 25-30% change in BPRS score. We found short-term data dichotomised to 'no clinical improvement' were not significantly different (1 RCT, n=66, RR 0.36 CI 0.1 to 1.0). However, by about five months, participants allocated to Morita therapy were more likely to have experienced improvement compared with standard care (1 RCT, n=76, RR 0.36 CI 0.1 to 0.9, NNT 5 CI 4 to 25). This was not our chosen primary outcome, but, from the limited data within the trials, is the nearest record we have to global overall improvement (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Average short-term BPRS continuous scores were non-significant (n=189, 3 RCTs, RR -4.33 CI -10.3 to 1.6) and contained considerable heterogeneity (I<SUP>2</SUP>=94%). <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> and <LINK REF="STD-Lv-2002" TYPE="STUDY">Lv 2002</LINK> reported BPRS data at medium term, which favoured Morita therapy (n=124, RR -5.19 CI -0.6 to -0.7), but data were heterogeneous (I<SUP>2</SUP>=83%). Even when the very poor quality trials are removed (<LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK>) this renders the outcome non-significant (1 RCT, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, n=66, WMD -1.70 CI -4.2 to 0.8). BPRS data in <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> contained wide confidence intervals (skewed data) and are reported in 'Other data' tables. When overall BPRS data are presented as percent change, these results favour the Morita therapy group (1 RCT, n=100, WMD percent change 3.90 CI 0.6 to 7.3), but medium-term data by <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK> were equivocal.</P>
<P>Only one study focused on post-schizophrenic depression symptoms using the HAMD scale. <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> defined a reduction on the HAMD score of less than 25% as no clinical improvement, and we found no significant difference between Morita therapy and standard care (1 RCT, n=104, RR 0.36 CI 0.1 to 1.1). On continuous outcomes, people treated by Morita therapy had lower HAMD score at endpoint after 12 weeks intervention (1 RCT, n=104, WMD -3.59 CI -5.6 to -1.5).</P>
<P>For negative symptoms two trials defined a reduction of less than 25% on the SANS scale as no clinically important improvement. Short-term data were equivocal (1 RCT, n=50, RR 0.89, CI 0.4 to 1.9), but medium-term assessment favoured Morita therapy (1 RCT, n=42 RR 0.25 CI 0.1 to 0.8, NNT 3 CI 2 to 8). Four studies reported continuous endpoint SANS data favouring Morita therapy (n=323, WMD -12.94 CI -21.6 to -4.3), but mean scores are heterogeneous (I<SUP>2</SUP>=97%). We reanalysed data with <LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> removed (poorly randomised studies) but heterogeneity remained high (I<SUP>2 </SUP>=82%). We found medium-term data favoured Morita therapy (1 RCT, n=76, WMD -4.57 CI -8.6 to -0.6) compared with standard care alone. Further SANS scores were reported by <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK>, <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> and <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> but contained wide confidence intervals (skewed data) and are reported in 'Other data tables'.</P>
<P>1.2.4 Quality of Life<BR/>
<LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> (n=100) used a Chinese modified Quality of Life Scale to assess the inpatient quality of life in the short term. Average score change were skewed but seemed to favour Morita therapy (t=15.6, p&lt;0.01).</P>
<P>1.2.5 Social functioning<BR/>Two studies used the ADL scale to assess daily living function. Morita therapy plus standard treatment did significantly improve the activities of daily living compared with standard treatment alone during short-term (1 RCT, n=104, WMD -4.14 CI -7.7 to -0.6) and medium-term (1 RCT, n=48 WMD -10.50 CI -12.5 to -8.5) assessments.</P>
<P>
<LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK> calculated the average per cent score of change of SDSS and found that Morita therapy performed better in reducing social disability (n=111, WMD 16.40 CI 9.7 to 23.1) during medium-term assessment. <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> also reported SDSS endpoint data, but contained wide confidence intervals and are reported in 'Other data tables'.</P>
<P>
<LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK> and <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> used a Chinese scale (IPROS) to measure social outcome of psychiatric rehabilitation specifically for inpatients. Morita therapy performed better in improving social function (n=80, WMD -45.87 CI -50.1 to -41.1) during short-term treatment by <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>. Data in <LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> were skewed but also favoured the Morita therapy group (t=13.6, p&lt;0.01).</P>
<P>1.2.6 Behaviour - NOSIE<BR/>In a ten weeks study, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>, reported how people allocated Morita therapy behaved less well than those in the standard care group (n=66, WMD average NOSIE score 15.20 CI 9.0 to 21.4). <LINK REF="STD-Wu-1999" TYPE="STUDY">Wu 1999</LINK> also reported data from the NOSIE scale, but data were skewed data, both for endpoint and change, although tended to favour the Morita therapy group see 'other data table'.</P>
<P>1.2.7 Adverse events<BR/>Only <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> (n=104) reported adverse events. Specific adverse events of somnolence (RR 0.83 CI 0.3 to 2.4) and postural hypotension (RR 1.33 CI 0.3 to 5.7) were not significantly different between groups. General TESS adverse events were reported by <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> and we found data equivocal (n=104, RR -0.18 CI -0.9 to 0.5).</P>
<P>2. COMPARISON 2. Morita THERAPY + STANDARD versus REHABILITATION + STANDARD CARE<BR/>We found two similar studies in terms of the study design, structure and style of paper writing and results. The major differences were the sample size (<LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> n=182 and <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK> n=120) and duration of treatment (six weeks and eight weeks respectively). Both Morita therapy and rehabilitation therapy had four phases in each study.</P>
<P>2.1 Leaving the study early<BR/>In these two short-term studies, 12 from each group in <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> and none from <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK> left early (n=302, RR 1.00 CI 0.5 to 2.1).</P>
<P>2.2 Mental state - BPRS<BR/>We found no significant difference for the outcome of no overall clinical improvement (1 RCT, n=120, RR less than 25% change of BPRS score at the end of study 0.89 CI 0.5 to 1.6). For continuous measures, Morita therapy showed better effect on mental state with lower BPRS score compared with people allocated to rehabilitation (2 RCTs, n=278, WMD -6.95 CI -9.3 to -4.6).</P>
<P>2.3 Insight<BR/>Patients insight was rated on a four-point scale according the clinicians judgement. People treated by Morita therapy had better insight than those treated by rehabilitation (2 RCTs, n=278, WMD -1.11 CI -1.3 to -0.91).</P>
<P>2.4 Social functioning - IPROS<BR/>Both trials used the Inpatient Psychiatric Rehabilitation Outcome Scale to measure social functioning. Results favoured Morita therapy (2 RCTs, n=278, WMD -18.14 CI -21.3 to -15.0) compared with standard care.</P>
<P>3. Small trial bias<BR/>The sample size of the studies included in the review ranged from 41 to 120. The outcome for which most trials were included (Comparison 01: 01 Leaving the study early nine trials, n=679) have very few events. There are too few trials and no real scatter events for a funnel plot to be possible.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-27 15:11:53 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2008-10-27 14:52:24 +0000" MODIFIED_BY="[Empty name]">
<P>To our knowledge, this is the only systematic review on the important topic of the value of Morita therapy to this patient group. We have tried to summarise and assimilate data as objectively as possible and present these results in a clear and comprehensible way. However, a systematic review is only as strong as its building blocks and there are several points of concern in the quality of the included trials. Overall we judged the study quality to be medium to poor. This probably means that any results we present are not strong and may well be biased in favour of the experimental intervention (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). The degree of this bias could be considerable.</P>
<P>1. COMPARISON 1. Morita THERAPY + STANDARD CARE versus STANDARD CARE<BR/>Although ten studies are included in this comparison the average size of trials is only 76 people. Morita therapy may not be common in many places but it is still widely used in highly populous countries. Further larger trials are needed.</P>
<P>1.1 Leaving the study early<BR/>Very few people (&lt;2%) left early and there were no differences between groups (n=761). This has not only to be a reflection of the acceptability of the two packages of care but also of a compliant care culture. We are unclear how this would generalise outside of China. In any event, we have no evidence that Morita therapy is in some way unacceptable.</P>
<P>1.2 Mental state<BR/>Participants and trialists invested time and effort rating mental state using several scales. It is difficult to know if the result justifies the effort on the part of everyone concerned.</P>
<P>The overall impression is mixed with findings both in favour of Morita therapy and equivocal as regards its efficacy. The number of people needed to be given Morita therapy in order for one to have a 25-30% percent improvement on the BPRS scale is about five (NNT 5 CI 4 to 25). For chronically ill people such a change could represent an important improvement should that improvement occur in key symptoms. However, we would surmise that most of the time people could experience such a change without dramatic improvements being obvious. The BPRS measurements could be recording a real but clinically limited change. We have no idea from trials whether even this improvement extends beyond the time in which treatment is being given. There is some other evidence from other reviews of behavioural interventions for people with schizophrenia that the immediate effects are not carried on beyond the period of treatment (<LINK REF="REF-Jones-2004" TYPE="REFERENCE">Jones 2004</LINK>).</P>
<P>When the BPRS data are presented as continuous outcomes there is very marked heterogeneity. This does not seem to be the result of inclusion of poor quality studies. We are not at all clear why the heterogeneity should remain. We have added the duration of treatment as a &#8216;user defined order&#8217; so that data may be sorted on this variable. This too does not make a convincing reason for the heterogeneity. In any case, heterogeneous or not, the differences in BPRS scores are, we suggest, not likely to be clinically important.</P>
<P>We have identified only one study focusing on depressed people with schizophrenia (<LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>). Morita therapy could be beneficial for the treatment of post-schizophrenia depression combined with antipsychotics and antidepressants but again we are unclear if the HAMD score decline of less than 25% is really clinically important (n=104, RR -0.36 CI -5.6 to -1.5), and even if it is we should have a larger longer study to replicate this finding and to see if Morita therapy could reduce the use of antidepressants combined with antipsychotics.</P>
<P>So few treatments show even a suggestion of effect on negative symptoms, clinicians and researchers are always eager to find any improvement from any treatment. It is, however, important not to clutch at straws. This review presents weak data from weak studies. Binary outcomes from two trials are equivocal, heterogeneous and of unclear clinical meaning (less than 25% decline in SANS). Continuous outcomes are statistically significant but grossly heterogeneous (I<SUP>2</SUP> =97%). The reason for the huge I<SUP>2</SUP> is partly from <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>. The participants of <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> had depressive symptoms (HAMD=18). Removal of <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>, does help, but the result remains heterogeneous (I<SUP>2</SUP> =68%). Because, within the heterogeneity, all of four studies (<LINK REF="STD-Chen-1999" TYPE="STUDY">Chen 1999</LINK>, <LINK REF="STD-Sheng-2006" TYPE="STUDY">Sheng 2006</LINK>, <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK> and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK>) did favour Morita therapy, we have retained the meta-analysis table for more detailed information. The difference in SANS scores, however, averages 13 points. For these disabled people we think this not likely to really make an important clinically noticeable difference.</P>
<P>1.3 Quality of Life<BR/>
<LINK REF="STD-Zhu-2002" TYPE="STUDY">Zhu 2002</LINK> is the only study to consider, measure and report quality of life. There are too few data to be clear on what the current data mean but increased use of such measures will help clarify this in future studies.</P>
<P>1.4 Social functioning<BR/>Measuring social impairment is difficult, but from the different ratings there is an impression that Morita therapy may improve general functioning in this domain. Continuous data from the Activity of Daily Living scale and Social Disability Screen Scale were both in favour of the Morita therapy group, but doubts remain for its application to only inpatient participants whose social functions are greatly limited. Changes in this outcome, however, seem to be a primary concern for those undertaking the trials. Even after 11 trials all findings are based on small short studies with no more than 152 people in any analysis. It would seem important that more data are produced on this set of findings. Currently data seem generally positive but are not convincing enough to change practice.</P>
<P>1.5 Behaviour<BR/>The non-skewed Nurses Observation Scale for Inpatients Evaluation data are the only results favouring standard care. The skewed data for the same scale, however, favoured Morita therapy. Aspects of Morita therapy could be problematic for inpatients and cause deterioration in behaviour; however, as with the putative positive effects of Morita therapy, it is important not to put too much emphasis on this one negative finding until it is replicated.</P>
<P>1.6 Adverse effects<BR/>We do realise that measuring adverse effects is rare in non-pharmacological trials, however, dependence, deterioration, tolerance and even addition are real issues where it comes to the talking/behavioural therapies. In reasons for leaving early <LINK REF="STD-Lu-1999" TYPE="STUDY">Lu 1999</LINK> did report that more in the Morita therapy left because of being uncooperative (not to a statistically significant extent) and <LINK REF="STD-Wei-2005" TYPE="STUDY">Wei 2005</LINK> did mention a few other potential adverse effects again none reaching conventional levels of statistical significance. Though definition of relapse varies in routine clinical practice, not one patient in the pooled sample of 679 experienced a relapse across the five short (6-12 weeks) and four longer trials (13-40 weeks). It is a concern that negative events could well be under reported.</P>
<P>2. COMPARISON 2. Morita THERAPY + STANDARD CARE versus REHABILITATION + STANDARD CARE</P>
<P>The results of about 10% failing to finish the full study in <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> and none leaving <LINK REF="STD-Cao-2003" TYPE="STUDY">Cao 2003</LINK> seems to us to suggest that <LINK REF="STD-Tang-2002" TYPE="STUDY">Tang 2002</LINK> may be slightly more general in its findings.</P>
<P>2.1 Mental state<BR/>Results favour the Morita therapy group (n=278, 2 RCTs, WMD about seven points decrease on BPRS). Again, this decline may not represent a huge change in clinical presentation but if it really exists is worthy of more investigation. This applies to the similarly homogeneous data for insight.</P>
<P>2.2 Social functioning<BR/>Finally, both trials used the Inpatient Psychiatric Rehabilitation Outcome Scale to measure social functioning. The almost identical and significant results from these two trials which favoured Morita therapy should be replicated.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2008-10-27 14:58:16 +0000" MODIFIED_BY="[Empty name]">
<P>Morita therapy is a kind of cultural-based psychological therapy related to Asia, particularly Japan and China. Participants in the included studies were all from the People's Republic of China. Morita therapy is very behavioural and prescriptive. We are unclear how this approach would generalise to care cultures in other areas. However, we are aware that some Morita is practiced outside of Asia (<LINK REF="REF-Wen-2001" TYPE="REFERENCE">Wen 2001</LINK>). We suspect that, in the context of family life, or longer-term professional support, people with schizophrenia are often involved in regimens of care that have elements that would be recognisable to those practicing Morita therapy. Otherwise the people in these trials are generally recognizable; they are clearly diagnosed with long-term care needs.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2008-09-18 18:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>We had hoped to be able to report on the effects of Morita therapy on relapse, ability to return to society, general impression of clinician, carer/other and the economic outcomes. None of these important outcomes were addressed. No claims beyond the end of the therapy itself that are made for Morita therapy are based on trials. Several of the included studies report data only on the intervention group. This omission does not allow us to make full use of these data and important information is lost. Other studies report only inexact p values, again rendering these data useless for this review. Of the usable data, often we are reporting the results of a single study per outcome. If trialists had agreed on a standard set of outcomes, rather than reporting the same outcome in many different ways, we would have stronger data to report. Also, all trials in this review are small (largest n=182) and are likely to be underpowered even for large effects in binary outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2008-10-27 15:11:53 +0000" MODIFIED_BY="[Empty name]">
<P>We have made many judgments in undertaking this review and are aware of several potential biases in what we have done. We have searched several databases and may have failed to identify relevant studies. We are conscious that the Japanese literature is not well covered in any of the sources we use. We have judged the studies to be of general poor quality and tempered our interpretation of the results accordingly. We could be being over-harsh but report all the data as best as we could extract for others to reconsider if necessary. We could, however, have been veering too much the other way as well. These trials are all small, some would consider very poorly designed, conducted and reported and undertaken often by people who could well wish for a positive effect of the Morita therapy that they are hardly blind to.  </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2008-09-20 19:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>We know of no other reviews of this type with the exception of our earlier version (<LINK REF="REF-He-2007" TYPE="REFERENCE">He 2007</LINK>). This update does add to that in sophistication and has the addition of one previously unidentified trial but does not substantially change our impression of the effects of this therapy for people with schizophrenia.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-25 14:55:10 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-27 15:13:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. People with schizophrenia</P>
<P>For people with long-term schizophrenia residual symptoms can be problematic. Currently the trial-based data on Morita therapy are weak and poor. However, there are more suggestions of gain than of loss. Morita therapy for schizophrenia remains an experimental intervention and may do some good but it would seem reasonable that people with schizophrenia ask that they receive such treatment within the context of a well designed, patient-focused randomised trial.</P>
<P>2. Clinicians<BR/>Clinicians may feel that Morita therapy is worth the time and effort. Many units would not be set up to undertake Morita therapy to the quality that we have seen in these randomised trials. It is feasible that the effects of this treatment, should they really exist, are not as marked if not undertaken by such committed practitioners. In any case, all the effects of Morita therapy reported in these weak trials are of, at best, moderate clinical importance. Should clinicians be practicing Morita therapy it is worth considering whether it is ethical to continue this form of care outside of a really well-designed and patient and clinician focused evaluative study. Other equally or more effective interventions may be more accessible.</P>
<P>3. Managers/Health Policy Makers<BR/>Service managers and health policy makers have to balance the costs and benefits of this treatment and whether it significantly improves outcomes for patients. Currently we have almost no data to support or to refute the use of Morita therapy over other therapies. Further studies are needed to address this.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-25 14:55:10 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>If the CONSORT recommendations (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) were followed in the reporting of future studies, there would be more data to consider, even from these trials. Much important data within the included studies were so poorly reported that clinicians, funders and recipients of care might have reason to feel let down by the research community.</P>
<P>Allocation concealment is a fundamental part of trial methodology. The means by which this is undertaken should be clearly reported. Double blind assessment of the outcomes of a psychological therapy is extremely difficult, and probably impossible. Trialists should, however, take every precaution to minimise the effect of biases by using blind or independent raters. These raters should have their blindness tested. More objective outcomes should be used, such as relapse, time of hospitalization, admission times rather than scale data.</P>
<P>A statistical expert should participate in these trials or be consulted during the design, analysis and reporting of clinical trials. Intention-to-treat analysis should be performed on all outcomes and all trial data should be made easily accessible. A minimal requirement should be that all data should, at least, be presented as numbers. In addition, continuous data should be presented for each group with means, standard deviations (or standard errors) and the number of participants. Data from graphs, 'p' values of differences and statements of significant or non-significant differences are of limited value.</P>
<P>2. Specific to Morita therapy trials<BR/>We do think that this review supports the need for more studies but realise that there would have to be very careful planning of such a study. We do not wish to belittle the preparation that precedes a large trial but suggest some elements of design that we thought may be useful from careful reading of the best available evidence (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Although many people in need of therapy to improve their social functioning may be in hospital, there are as many, if not more, at home. Although Morita therapies have mostly been practiced within hospital inpatient settings we see no reason not to implement this package of care within, for example, day care centres (<LINK REF="REF-Catty-2007" TYPE="REFERENCE">Catty 2007</LINK>).</P>
<P>Outcomes should be clear and clinically useful but if authors are to persist in using continuous scale-derived data these tools should be standardised, and peer reviewed (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Some of the scales are not international but should have some degree of at least local verification. In addition patient-focused outcomes such as healthy days, family burden, quality of life, should not be forgotten and, some recording of economic evaluations (cost-effectiveness and cost-benefit) of the two intervention strategies would be most welcome.</P>
<P>[Note: the 10 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-27 15:16:56 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Judy Wright, Tessa Grant, Sam Roberts, and Beth York of the Cochrane Schizophrenia Group for their help, Dr. Stefan Leucht supporting and Prof. Clive E. Adams editing and supporting this review. Our great and enduring thanks also go to John Davis whose enduring vision for this work translates into practice and reviews.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-18 18:14:53 +0100" MODIFIED_BY="[Empty name]">
<P> None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-18 18:31:11 +0100" MODIFIED_BY="[Empty name]">
<P>Yanling He - protocol preparation, study selection, data extraction, review completion, conversion to Revman 5, update.</P>
<P>Chunbo Li - protocol preparation, study selection, data extraction, review completion, conversion to Revman 5, update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-09-18 18:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Upgrade of review into RevMan 5 resulted in changed order of text within 'Methods' section - but no fundamental changes to the conduct of the review or the update.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-07-05 13:56:57 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-01-31 13:11:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2003" MODIFIED="2011-01-31 13:10:44 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-01-31 13:10:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao HJ, Wang SH, You HF, Fan FL, Zhang J</AU>
<TI>Comparative study of new morita therapy and rehabilitation therapy on recovery of schizophrenia</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>21</NO>
<PG>2270-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1999" NAME="Chen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen SQ</AU>
<TI>The therapeutic effect of morita therapy for schizophrenia patients in recovery period</TI>
<SO>Sichuan Mental Health</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4</NO>
<PG>237-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1999" NAME="Lu 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Tian M, Zhang Q</AU>
<TI>A clinical study on effects of neo morita therapy in the treatment of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>4</NO>
<PG>286-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lv-2002" MODIFIED="2011-01-31 13:08:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lv 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-01-31 13:08:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lv JJ, Chu YZ, Bai YG, Lv FQ, Lu DZ</AU>
<TI>The rehabilitative effects of morita therapy for chronic schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>2</NO>
<PG>122-4</PG>
<IDENTIFIERS MODIFIED="2011-01-31 12:57:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2006" MODIFIED="2011-01-31 13:08:26 +0000" MODIFIED_BY="[Empty name]" NAME="Sheng 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-31 13:08:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng JL, Shen Y, Kong LF, Zhu L, Gu YJ, Chen PY</AU>
<TI>The efficacy of modified morita therapy for chronic schizophrenia patients with residual symptoms</TI>
<SO>Chinese Journal of Rehabilitation Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>9</NO>
<PG>834-6</PG>
<IDENTIFIERS MODIFIED="2011-01-31 12:54:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2002" NAME="Tang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang W, Wang Z</AU>
<TI>Modified morita therapy for rehabilitation of schizophrenia in comparison with rehabilitation therapy</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>2</NO>
<PG>88-90, 93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0312"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tang W, Wang Z</AU>
<TI>Modified morita therapy on schizophrenic patients</TI>
<SO>12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2005500905"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1994" MODIFIED="2008-09-23 13:14:22 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Ma W, Sun H</AU>
<TI>Controlled study of modified morita therapy for chronic schizophrenia</TI>
<SO>Chinese Journal of Health Psychology</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>4</NO>
<PG>253-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0209"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:13:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XY, Ma WY, Sun HX, Jiang T, Lu QZ, Zhang XF, et al</AU>
<TI>Comparison of bone mineral density among chromic schizophrenia patients before and after Morita therapy</TI>
<TO>Figure 07</TO>
<SO>Chinese Journal of Osteoporosis</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-23 13:14:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XY, Sun HX, Lu QZ, Ma WY, Zhang SH, An JR, et al</AU>
<TI>The application of Morita therapy in chronic schizophrenia</TI>
<TO>Figure 08</TO>
<SO>Health Psychology Journal</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2011-01-31 13:08:39 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CX, Wang RJ, Sun XH</AU>
<TI>Morita therapy in treatment of inpatients with schizophrenia- MMPI analysis</TI>
<TO>Figure 05</TO>
<SO>Chinese Journal of Behavioral Science</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>1</NO>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-01-31 13:08:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang R</AU>
<TI>Morita therapy for 33 cases of analysis of personality characteristics in patients with schizophrenia</TI>
<TO>33</TO>
<SO>Nervous Diseases and Mental Hygjene</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>6</NO>
<PG>439-40</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:03:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang RJ, Yuan LL</AU>
<TI>Morita therapy in treatment of inpatients with schizophrenia</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>6</NO>
<PG>404-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0012S1"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2011-01-31 13:11:06 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-01-31 13:11:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Guan T, Xue CY, Fu XQ, Qi JR, Liu JY, et al</AU>
<TI>A control study on modified morita therapy for rehabilitation of chronic schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1322-3</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:01:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2005" MODIFIED="2011-01-31 13:04:19 +0000" MODIFIED_BY="[Empty name]" NAME="Wei 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-31 13:03:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei Q</AU>
<TI>Effect of new morita therapy plus antipsychotic drugs in ameliorating post-schizophrenia depression</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>32</NO>
<PG>72-5</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:03:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1999" NAME="Wu 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu H, Wang Z, Zhang H</AU>
<TI>Morita therapy in treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>12</NO>
<PG>84-87</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0209"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2002" MODIFIED="2011-01-31 13:07:05 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu L, Lu W, Yi Z, Long B, Zhu YH, Fei M</AU>
<TI>Influence of morita therapy on quality of life in schizophrenic patients</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>5</NO>
<PG>273-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu L, Wu G, Long B, Yi ZH, Zhu YH, Fei M</AU>
<TI>Morita therapy affecting factors of quality of life in long-term in-patients with schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>3</NO>
<PG>151-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0209"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-01-31 12:59:37 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2000" MODIFIED="2008-09-23 13:16:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-23 13:16:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma WY, Wang XY, Sun HX, Zhang SH, Han SM</AU>
<TI>Clinical observation of morita therapy 'bed-stage' for chronic schizophrenia</TI>
<TO>Figure 09</TO>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>1</NO>
<PG>59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2006" MODIFIED="2011-01-31 12:59:37 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-31 12:59:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma X, Yuan L, Yu X</AU>
<TI>Effect of morita therapy on mental status of schizophrenia patients in recovery period</TI>
<TO>(Figure 13)</TO>
<SO>Chinese Journal of Health Psychology</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>2</NO>
<PG>203-5</PG>
<IDENTIFIERS MODIFIED="2011-01-31 12:59:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1998" NAME="Wang 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XY</AU>
<TI>Morita therapy for the rehabilitation of chronic schizophrenia</TI>
<TO>Figure 10</TO>
<SO>Health Psychology Journal</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>199</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2008-09-23 13:19:30 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-23 13:19:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang WL</AU>
<TI>Add on morita therapy for chronic schizophrenia</TI>
<TO>Figure 13</TO>
<SO>Occupation and Health</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>3</NO>
<PG>108-09</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2001" MODIFIED="2008-09-23 13:19:47 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-23 13:19:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou YL, Han LX, Hou LP, Lu S, Chang AG</AU>
<TI>The application of modified morita therapy among 69 cases with schizophrenia at stable stage</TI>
<TO>Figure 12</TO>
<SO>Medical Journal of the Chinese People's Armed Police Forces</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>4</NO>
<PG>228-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-07-05 13:56:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2002" MODIFIED="2012-07-05 13:45:14 +0100" MODIFIED_BY="[Empty name]" NAME="Fan 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-05 13:45:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan Y, Wang B, Zhai X</AU>
<TI>A test for the reliability and validity of SCL-90 in middle school student</TI>
<SO>&#22235;&#24029;&#31934;&#31070;&#21355;&#29983;</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>3</NO>
<PG>132-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001" MODIFIED="2012-07-05 13:45:17 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-07-05 13:45:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CX, Wang RJ, Sun XH</AU>
<TI>Morita therapy in treatment of inpatients with schizophrenia- MMPI analysis</TI>
<TO>&#26862;&#30000;&#30103;&#27861;&#27835;&#30103;&#20303;&#38498;&#31934;&#31070;&#20998;&#35010;&#30151;MMPI &#27979;&#26597;&#20998;&#26512;</TO>
<SO>Chinese Journal of Behavioral Science</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>1</NO>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1994a" MODIFIED="2012-07-05 13:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1994a" YEAR="1994">
<REFERENCE MODIFIED="2012-07-05 13:46:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XY, Ma WY, Sun HX, Jiang T, Lu QZ, Zhang XF, et al</AU>
<TI>Comparison of bone mineral density among chronic schizophrenia patients before and after morita therapy</TI>
<SO>Chinese Journal of Osteoporosis</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-05 13:45:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XY, Sun HX, Lu QZ, Ma WY, Zhang SH, An JR, et al</AU>
<TI>The application of morita therapy in chronic schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2012-07-05 13:47:12 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004" YEAR="2002">
<REFERENCE MODIFIED="2012-07-05 13:45:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Guan T, Xue CY, Fu XQ, Qi JR, Liu JY, et al</AU>
<TI>A control study on modified morita therapy for rehabilitation of chronic schizophrenia</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24247;&#22797;&#27835;&#30103;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1322-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yue-2002" MODIFIED="2011-01-31 13:08:52 +0000" MODIFIED_BY="[Empty name]" NAME="Yue 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-01-31 13:08:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yue Y, Song LS, Chen Y</AU>
<TI>A comparison study of modified morita therapy with rehabilitation therapy for schizophrenia inpatients</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>13</NO>
<PG>1956</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:04:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5085__x6155__x541b__x002c_-2010" MODIFIED="2012-07-05 13:45:28 +0100" MODIFIED_BY="[Empty name]" NAME="&#20613;&#24917;&#21531;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-05 13:45:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20613;&#24917;&#21531;, &#24429;&#20048;&#23384;, &#35832;&#24800;&#33805;, &#40644;&#24800;&#29645;, &#26417;&#21033;&#33464;</AU>
<TI>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#22312;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30149;&#20154;&#20013;&#30340;&#24212;&#29992;&#30740;&#31350; Modified Morita therapy in patients with chronic schizophrenia</TI>
<SO>&#25252;&#29702;&#31649;&#29702;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>12</NO>
<PG>884-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5434__x6653__x8679_-2009" MODIFIED="2012-07-05 13:45:31 +0100" MODIFIED_BY="[Empty name]" NAME="&#21556;&#26195;&#34425; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-05 13:45:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21556;&#26195;&#34425;</AU>
<TI>Observation on curative effect of improved morita therapy for schizophrenia patients in rehabilitation period</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#29992;&#20110;&#24247;&#22797;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Nursing Research [&#25252;&#29702;&#30740;&#31350;]</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1629-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f6d__x4e50__x5b58__x002c_-2010" MODIFIED="2012-07-05 13:49:41 +0100" MODIFIED_BY="[Empty name]" NAME="&#24429;&#20048;&#23384;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-05 13:49:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24429;&#20048;&#23384;, &#40644;&#24935;&#29577;, &#20052;&#24800;&#21531;, &#35832;&#24800;&#33805;, &#37036;&#26149;&#21326;, &#21016;&#29577;&#20848;, et al</AU>
<TI>Modified morita therapy for chronic schizophrenia</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>6</VL>
<PG>662-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6e29__x4e91__x8f89__x002c_-2010" MODIFIED="2012-07-05 13:51:34 +0100" MODIFIED_BY="[Empty name]" NAME="&#28201;&#20113;&#36745;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-05 13:51:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#28201;&#20113;&#36745;, &#26446;&#24800;&#20185;, &#24247;&#24314;&#21326;, &#40644;&#33465;</AU>
<TI>Modified morita therapy on the rehabilitation of chronic schizophrenia</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#27835;&#30103;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#24247;&#22797;&#25928;&#26524;&#35780;&#20215;</TO>
<SO>Modern Preventive Medicine</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>2279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x6c49__x632f__x002c_-2009" MODIFIED="2012-07-05 13:54:01 +0100" MODIFIED_BY="[Empty name]" NAME="&#33891;&#27721;&#25391;, 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-05 13:54:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33891;&#27721;&#25391;, &#33970;&#37329;&#29577;, &#23385;&#26790;&#26376;, &#38889;&#20029;&#38686;, &#23385;&#40527;, &#36335;&#33521;&#26234;</AU>
<TI>Modified morita therapy on the rehabilitation of schizophrenic patients. A comparative study of quality of life</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#23545;&#24247;&#22797;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#24433;&#21709;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>5</VL>
<PG>525-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x95fe__x91d1__x6770__x002c_-2010" MODIFIED="2012-07-05 13:56:57 +0100" MODIFIED_BY="[Empty name]" NAME="&#38398;&#37329;&#26480;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-05 13:56:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38398;&#37329;&#26480;, &#25308;&#26377;&#26681;, &#40644;&#32988;&#21326;, &#21494;&#25104;&#21551;, &#21608;&#23159;&#23159;</AU>
<TI>Morita therapy improved long-term outcome of chronic schizophrenia</TI>
<TO>&#25913;&#33391;&#26862;&#30000;&#30103;&#27861;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36828;&#26399;&#30103;&#25928;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>4</VL>
<PG>238-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OLZ020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1983" NAME="Andreasen 1983" NOTES="&lt;p&gt;Scale for the Assessment of Negative Symptoms - SANS&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative symptoms in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1983</YR>
<VL>39</VL>
<PG>784-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-2007" MODIFIED="2008-08-07 11:24:08 +0100" MODIFIED_BY="[Empty name]" NAME="Buckley 2007" TYPE="COCHRANE_REVIEW">
<AU>Buckley LA, Pettit TACL, Adams CE</AU>
<TI>Supportive therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-08-07 11:24:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:24:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004716.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Catty-2007" MODIFIED="2008-08-07 11:00:40 +0100" MODIFIED_BY="[Empty name]" NAME="Catty 2007" TYPE="COCHRANE_REVIEW">
<AU>Catty JS, Burns T, Comas A, Poole Z</AU>
<TI>Day centres for severe mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-08-07 11:00:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:00:09 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001710.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-1995" MODIFIED="2008-09-23 13:25:14 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chen P, Yu ES, Zhang M, Liu WT, Hill R, Katzman R</AU>
<TI>ADL dependence and medical conditions in chinese older persons: A population - based survey in Shanghai, China</TI>
<SO>Journal of American Geriatric Society</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>4</NO>
<PG>378-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chilvers-2006" MODIFIED="2008-08-07 11:03:05 +0100" MODIFIED_BY="[Empty name]" NAME="Chilvers 2006" TYPE="COCHRANE_REVIEW">
<AU>Chilvers R, Macdonald GM, Hayes AA</AU>
<TI>Supported housing for people with severe mental disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-08-07 11:02:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:02:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000453.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DoH-2001" NAME="DoH 2001" NOTES="&lt;p&gt;DoH 2001. Department of Health. . London: Department of Health, 2001.&lt;/p&gt;" TYPE="BOOK">
<AU>Department of Health</AU>
<SO>Treatment choice in psychological therapies and counselling evidence based clinical practice guideline</SO>
<YR>2001</YR>
<PB>Department of Health</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-09-23 13:29:00 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiol</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>Issue 3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honigfeld-1965" MODIFIED="2008-09-23 13:31:20 +0100" MODIFIED_BY="[Empty name]" NAME="Honigfeld 1965" TYPE="JOURNAL_ARTICLE">
<AU>Honigfeld G, Klett C J</AU>
<TI>The nurses' observation scale for inpatient evaluation: A new scale for measuring improvement in chronic schizophrenia</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1965</YR>
<VL>21</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2004" MODIFIED="2008-08-07 11:22:15 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2004" TYPE="COCHRANE_REVIEW">
<AU>Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C</AU>
<TI>Cognitive behaviour therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-07 11:22:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:22:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000524.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2008-09-23 13:31:59 +0100" MODIFIED_BY="[Empty name]" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-1994" MODIFIED="2008-09-23 13:56:14 +0100" MODIFIED_BY="[Empty name]" NAME="Li 1994" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Hu X, Jin D, Tian W, Phillips MR</AU>
<TI>A rating instrument for the evaluation of in-patient rehabilitation programmes in China. Results of reliability and validity testing</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>24</VL>
<NO>Suppl</NO>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-1995" MODIFIED="2008-09-23 13:58:07 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lu YZ, Tiandai Xinxiong</AU>
<TI>A brief introduction of the research advance of morita therapy for schizophrenia in Japan</TI>
<TO>Figure 02</TO>
<SO>Chinese Mental Health Journal</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>271-3, 278</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-1989" MODIFIED="2008-10-20 11:18:47 +0100" MODIFIED_BY="[Empty name]" NAME="McEvoy 1989" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L</AU>
<TI>Insight in schizophrenia. Its relationship to acute psychopathology</TI>
<SO>J Nerv Ment Dis</SO>
<YR>1989</YR>
<VL>177</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntosh-2006" MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]" NAME="McIntosh 2006" TYPE="COCHRANE_REVIEW">
<AU>McIntosh AM, Conlon L, Lawrie SM, Stanfield AC</AU>
<TI>Compliance therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<PB>John Wiley &amp; sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 13:57:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003442.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2003" NAME="NICE 2003" TYPE="BOOK">
<AU>National Institute for Clinical Excellence</AU>
<SO>Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care</SO>
<YR>2003</YR>
<PB>Gaskell</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1985" MODIFIED="2008-09-23 14:00:59 +0100" MODIFIED_BY="[Empty name]" NAME="NIMH 1985" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Mental Health</AU>
<TI>Treatment Emergent Symptoms Scale -- write-in (TESS)</TI>
<SO>Psychopharmacological Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<PG>1069-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Report</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pekkala-2002" MODIFIED="2008-08-07 11:25:08 +0100" MODIFIED_BY="[Empty name]" NAME="Pekkala 2002" TYPE="COCHRANE_REVIEW">
<AU>Pekkala E, Merinder L</AU>
<TI>Psychoeducation for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-08-07 11:25:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:25:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pharoah-2006" MODIFIED="2008-08-07 11:23:16 +0100" MODIFIED_BY="[Empty name]" NAME="Pharoah 2006" TYPE="COCHRANE_REVIEW">
<AU>Pharoah F, Mari J, Rathbone J, Wong W</AU>
<TI>Family intervention for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-08-07 11:23:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-07 11:23:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000088.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1980" MODIFIED="2008-09-23 14:03:57 +0100" MODIFIED_BY="[Empty name]" NAME="Reynolds 1980" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds DK, Keifer CW</AU>
<TI>Cultural adaptability as an attribute of therapies: the case of morita psychotherapy</TI>
<SO>Culture, Medicine and Psychiatry</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>4</NO>
<PG>395-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shen-1985" MODIFIED="2008-09-23 13:23:11 +0100" MODIFIED_BY="[Empty name]" NAME="Shen 1985" TYPE="BOOK">
<AU>Shen Y, Wang, C</AU>
<SO>A handbook of epidemiological investigation of mental illness</SO>
<YR>1985</YR>
<PB>Renming Health Press</PB>
<CY>Beijing</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11-31, 42-67"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Song-1996" NAME="Song 1996" TYPE="JOURNAL_ARTICLE">
<AU>Song LS, Zhang MY, Wu HM</AU>
<TI>The measurement and testing of quality of life scale for community psychotic patients</TI>
<SO>Shanghai Archive of Psychiatry</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>4</NO>
<PG>255-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suzuki-1989" MODIFIED="2008-09-23 14:04:22 +0100" MODIFIED_BY="[Empty name]" NAME="Suzuki 1989" TYPE="JOURNAL_ARTICLE">
<AU>Suzuki T</AU>
<TI>The concept of neurasthenia and its treatment in Japan</TI>
<SO>Culture, Medicine and Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>2</NO>
<PG>187-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takeda-1964" NAME="Takeda 1964" TYPE="JOURNAL_ARTICLE">
<AU>Takeda K</AU>
<TI>Morita therapy</TI>
<SO>Journal of Religion and Health</SO>
<YR>1964</YR>
<VL>3</VL>
<PG>335-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wen-2001" MODIFIED="2008-09-23 14:04:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wen QR</AU>
<TI>Development of morita therapy in China</TI>
<SO>Health Psychology Journal</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-09-20 19:36:27 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-He-2007" MODIFIED="2008-09-20 19:36:27 +0100" MODIFIED_BY="[Empty name]" NAME="He 2007" TYPE="COCHRANE_REVIEW">
<AU>He Y, Li C</AU>
<TI>Morita therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-20 19:36:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-20 19:35:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006346"/>
<IDENTIFIER MODIFIED="2008-09-20 19:36:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17253588"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-07-05 13:45:46 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-25 14:56:30 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-03 10:21:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Cao-2003">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blinding: single - rated independently.<BR/>Duration: 8 weeks of treatment and then rated outcome*.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=120.<BR/>Age: mean 39 years (SD=9). <BR/>Sex: M 72, F 48.<BR/>History: inpatients, duration ill ~13 years (SD ~9), times in hospital mean 3.4 (SD 2.7), Days in hospital 1.8 (SD=0.5) months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Morita therapy + standard care: 4 phases, a. bed phase + diary, 1 week; b. light work, discussion, reading, 2 weeks; c. heavy work, diary, physical exercise, 2 weeks; d. social/communication skills, 1 week; total 6 weeks. N=60.<BR/>2. Rehabilitation + standard care: 4 phases, a. observation 1 week; b. passive training, music, physical exercise, 2 weeks; c. active participation in entertainiment and physical exercise, 2 weeks; d. orgainise party to show what they have learnt, 1 week; total 6 weeks. N=60.</P>
<P>Standard care = medication CPZ equivelant 382 mg (SD=136).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early. <BR/>Mental state: BPRS, clinical improvement - defined by BPRS % of endpoint change (&lt;25% = no improvement), insight - clinicians judgement **.<BR/>Social functioning: IPROS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* The Morita group was divided into three with 20 for each, and each 20 have 8 weeks of treatment consequtively.<BR/>** Insight of psychotic symptoms: 1-4 (high=poor)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chen-1999">
<CHAR_METHODS>
<P>Allocation: quasi-randomised, registration number odd or even.<BR/>Blinding: no.<BR/>Duration: 12 weeks of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=73.<BR/>Age: mean ~30 year (SD~6).<BR/>Sex: M 43, F 30.<BR/>History: inpatients, duration ill ~5 years (SD~3).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Modified Morita therapy + standard care: The first phase was modified.12 weeks in total. N=35.</P>
<P>2. Standard care: N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-17 12:37:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-1999">
<CHAR_METHODS>
<P>Allocation: randomised, block.<BR/>Blinding: single - rated independently.<BR/>Duration: 6 months of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R, DSM-III-R).<BR/>N=120.<BR/>Age: mean ~ 32 years (SD~7).<BR/>Sex: M 58, F 62.<BR/>History: inpatient, duration ill mean ~7 years (SD~6).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-17 12:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Modified Morita therapy + standard care 4 phases, total 6 months. N=60.<BR/>2. Standard care: antipsychotics. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS.<BR/>Social functioning: SDSS<BR/>Medium term*.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The outcome is the percent of score change.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lv-2002">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blinding: single - rated independently.<BR/>Duration: 5 months of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=76.<BR/>Age: range 40-65, mean ~48 years (SD~8).<BR/>Sex: M 50, F 36.<BR/>History: inpatients, duration ill ~18 years (SD 8).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Modified Morita therapy + standard care: dose CPZ equivalent 626 mg (SD 97): 3 phases, a. bed phase, 2-3 weeks; b. work phase, 8-12 weeks; c. rehabilitation phase: social/communication skills, 3-4 weeks; total 13-19 weeks. N=38.</P>
<P>2. Standard care: dose CPZ equivalent 649 mg/day. N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS, clinical improvement defined by the study as BPRS total score change, less than 30%=no improvement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-03 10:21:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2006">
<CHAR_METHODS MODIFIED="2008-07-17 12:57:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: quasi-randomised, registration number odd or even.<BR/>Blinding: single blinding, two raters did not conduct treatment.<BR/>Duration: 6 weeks of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-03 10:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=82.<BR/>Age: mean ~44 year (SD~10).<BR/>Sex: M 82.<BR/>History: chronic inpatients, duration ill ~22 years (SD~9).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-03 10:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Modified Morita therapy + standard care: 4 phases, a. bed phase, 1 week; b. light work, 2 weeks; c. heavy work, 2 weeks; d. social/communication skills, 1 week; total 6 weeks. N=41.</P>
<P>2. Standard care: antipsychotics. N=41.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-17 12:54:24 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: SANS, insight scale*.<BR/>Social functioning: IPROS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-17 12:55:04 +0100" MODIFIED_BY="[Empty name]">
<P>* Insight of psychotic symptoms: high=good.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tang-2002">
<CHAR_METHODS>
<P>Allocation: randomised, block.<BR/>Blinding: single - rated independently.<BR/>Duration: 6 weeks of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=182.<BR/>Age: range 18-65, mean ~41 years.* <BR/>Sex: M 96, F 62.*<BR/>History: inpatients 1-3 months, stable, duration ill ~13.5 (SD 9.7) years, times in hospital mean 3.3 (SD 2.7), in hospital 1.7 months (SD 0.6).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Morita therapy + standard care: 4 phases, a. bed phase + diary, 1 week; b. light work, discussion, reading, 2 weeks; c. heavy work, diary, physical exercise, 2 weeks; d. social/communication skills, 1 week; total 6 weeks. N=91.</P>
<P>2. Rehabilitation + standard care: 4 phases, a. observation 1 week; b. passive training, music, physical exercise, 2 weeks; c. active participation in entertainiment and physical exercise, 2 weeks; d. orgainise party to show what they have learnt, 1 week; total 6 weeks. N=91.</P>
<P>Standard care = medication CPZ equivelant 327 mg (SD 146).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, insight - clinicians judgement **.<BR/>Social functioning: IPROS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Data calculated for people who completed study (n=158).<BR/>** Insight of psychotic symptoms: 1-4 (high=poor)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1994">
<CHAR_METHODS>
<P>Allocation: randomly selected, no detail about dividing groups.<BR/>Blinding: single blind - rater.<BR/>Duration: 10 months of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=48.<BR/>Age: mean ~ 40 years (SD~7).<BR/>Sex: all male.<BR/>History: inpatient, illness duration ~ 16 years (SD~6), times in hospital ~ 3.5 (SD 1.7), treatment days in hospital mean ~ 38 months (SD 26), control days in hospital mean 50 months (SD 54).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Modified Morita therapy + standard care: modified to extend to 10~12 months with 4 phases and social and life skill training enhanced. N=30.</P>
<P>2. Standard care. N=18.</P>
<P>Standard care: with maintenance treatment with 1/3 of regular dose of medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS. <BR/>Social functionning: ADL, SDSS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2000">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blinding: no information.<BR/>Duration: 10 weeks of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=66.<BR/>Age: range 15-59, mean ~36 years (SD~10).<BR/>Sex: M 46, F 20.<BR/>History: inpatients, duration ill ~7.6 years (SD~6.6).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Modified Morita therapy + standard care: dose CPZ equivalent 721.84 mg (SD 336.42): 3 phases, a. bed phase, 1 weeks; b. work phase, 2 weeks; c. rehabilitation phase: 5 weeks, d. phase 4: 2 weeks. N=33.</P>
<P>2. Standard care: dose CPZ equivalent 664.85 mg (SD 319.87). N=33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS, NOSIE. clinical improvement defined by the study as BPRS total score change, less than 25%=no improvement. </P>
<P>Unable to use -<BR/>Personality questionaire: MMPI (outcome not included on protocol).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2002">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blinding: no.<BR/>Duration: 4 months of treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=42.<BR/>Age: mean ~38 years (SD~10).<BR/>Sex: no information.<BR/>History: inpatients, duration ill ~14 years (SD~6), times in hospital ~3.5, time in hospital ~2.5 years (SD~1.3).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Modified Morita therapy + standard care: dose CPZ equivalent 389 mg (SD 211): a. bed phase, 3 weeks; b. work phase, merged regular phase II and phase III, not clear in terms of number of phases and the total duration of treatment. N=21.</P>
<P>2. Standard care: dsoe CPZ equivalent 368 mg (SD 212). N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: Clinical improvement defined by the study as SANS total score change**</P>
<P>Unable to use - <BR/>Mental state: BPRS (no total score or score of change in total), SANS (no endpoint data of control group).**</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Clinical improvement classified into fours: recovered, much improvement, some improvement and no improvement. criteria not described.<BR/>** paper states that there is a statistically significant difference between experimental and control endpoint (p&lt;0.01) for SANS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wei-2005">
<CHAR_METHODS>
<P>Allocation: randomised, block.<BR/>Blinding: no.<BR/>Duration: 12 weeks treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: post schizophrenia depression (CCMD-3).<BR/>N=164 (60 excluded, 18 refuse, 42 did not meet inclusion criteria).<BR/>Age: mean ~38 years (SD~6).<BR/>Sex: M 63, F 41.<BR/>History: inpatients, duration ill ~ 10 years (SD~5).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Morita therapy + standard care: dose CPZ equivalent 375.26 mg (SD 94.53), venlafaxine 128.56mg/d (SD 36.74), 4 phases, a. bed phase, 1 week; b. light work, 4 weeks; c. heavy work, 4 weeks; d. rehabilitation phase: social/communication skills, 3 weeks; total 12 weeks. N=52.</P>
<P>2. Standard care: dose CPZ equivalent 377.23 mg (SD 92.56, venlafaxine 130.48(SD 35.23)mg/d). N=52.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: HAMD, SANS, clinical improvement defined by the study as HAMD total score change, less than 25%=no improvement.<BR/>Adverse events: TESS.<BR/>Social functioning: SDSS, ADL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wu-1999">
<CHAR_METHODS>
<P>Allocation: randomised select patients but not clear about dividing groups.<BR/>Blinding: no detail.<BR/>Duration: 8 weeks treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=50.<BR/>Age: mean ~40 years (SD~9).<BR/>Sex: M 50.<BR/>History: inpatients, illness duration: ~13 years (SD~8).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Morita therapy + standard care: dose CPZ equivalent 428 mg (SD 180): 4 phases, a. bed phase, 1 week; b. light work, 2 weeks; c. heavy work, 3 weeks; d. rehabilitation phase: 2 weeks; total 8 weeks. N=25.</P>
<P>2. Standard care: dose CPZ equivalent 414 mg (SD 212). N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, SANS, clinical improvement defined by the study as total score change, equal or less than 25%=no improvement.<BR/>Behaviour: NOSIE.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-2002">
<CHAR_METHODS>
<P>Allocation: quasi-randomised, draw 20 from each of the 5 wards for 100 and divided into two groups<BR/>Blinding: no.<BR/>Duration: 8 weeks treatment and then rated outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2R).<BR/>N=100.<BR/>Age: mean ~47 years (SD~8).<BR/>Sex: M 80, F 20.<BR/>History: inpatients, duration ill ~ 22 years (SD~9).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Morita therapy + standard care: dose CPZ equivalent 365 mg (SD 156)): 4 phases, a. bed phase, 1 week; b. light work, 2 weeks; c. heavy work, 3 weeks; d. rehabilitation phase: 2 weeks; total 8 weeks. N=50.</P>
<P>2. Standard care: dose CPZ equivalent 353 mg (SD 151). N=50.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS, SANS (no control data).*<BR/>Social function: IPROS (no control data).<BR/>Quality of life: QOLS (no control data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* Only overall score at endpoint of Morita group reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL - Activity of Daily Living<BR/>BPRS - Brief Psychotic Rating Scale<BR/>CCMD-2R - Chinese Classification of Mental Disorder, version 2, revised<BR/>CPZ - Chlorpromazine<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental Disorders, version 3, revised<BR/>HAMD - Hamilton Rating Scale for Depression<BR/>IPROS - Inpatient Psychiatric Rehabilitation Outcome Scale<BR/>NOSIE - Nurses' Observation Scale for Inpatients Evaluation<BR/>QOLS - Quality of Life Scale<BR/>SANS - Scale of Assessment for Negative Symptoms<BR/>SDSS - Social Disability Screen Scale<BR/>TESS - Treatment Emergent Symptom Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-20 15:09:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:51:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:51:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-20 15:09:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-20 15:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: numbers of patients were inconsistent.</P>
<P>Intervention: intervention+standard care vs standard care, not Morita therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:52:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:52:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-07-25 14:56:30 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1994a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 15:06:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yue-2002">
<CHAR_METHODS MODIFIED="2008-10-20 15:06:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-25 14:56:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5085__x6155__x541b__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-25 14:56:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5434__x6653__x8679_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f6d__x4e50__x5b58__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:51 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6e29__x4e91__x8f89__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x6c49__x632f__x002c_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:54 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-05 14:03:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x95fe__x91d1__x6770__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-05 14:03:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-17 18:51:03 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-17 13:12:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:30:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2003">
<DESCRIPTION>
<P>"Randomised" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:32:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-1999">
<DESCRIPTION>
<P>By registration number - odd or even</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:34:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-1999">
<DESCRIPTION>
<P>Matched by age, gender, course and educational level - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:36:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lv-2002">
<DESCRIPTION>
<P>"Randomised" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 13:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sheng-2006">
<DESCRIPTION>
<P>By registration number - odd or even.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:13:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2002">
<DESCRIPTION>
<P>Randomised method was draw lots. Numbers of two groups were same.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:15:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1994">
<DESCRIPTION>
<P>"Randomised" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:15:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>"Randomised" - no further details..</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>"Randomised" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:49:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2005">
<DESCRIPTION>
<P>The randomised method was draw lots. The numbers of two groups were same.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:26:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-1999">
<DESCRIPTION>
<P>Randomly selected - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:27:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>Randomly drawn from 5 wards - no further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-17 12:57:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-15 17:02:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2003">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 12:00:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1999">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 12:22:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-1999">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 12:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lv-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 12:57:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheng-2006">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 12:56:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tang-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:05:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1994">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:12:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:52:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2005">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 14:01:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-1999">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 14:12:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-09-17 18:48:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-17 18:48:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2003">
<DESCRIPTION>
<P>Raters did not treat participants - no other description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 17:32:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-1999">
<DESCRIPTION>
<P>Therapist provided evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 17:34:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-1999">
<DESCRIPTION>
<P>Single blinding, two raters did not conduct treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 17:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lv-2002">
<DESCRIPTION>
<P>Single blinding, two raters did not conduct treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-17 12:58:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheng-2006">
<DESCRIPTION>
<P>Two raters did not conduct treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-17 08:12:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2002">
<DESCRIPTION>
<P>Nurses provided evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-17 08:15:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-1994">
<DESCRIPTION>
<P>Single blinding, four raters did not conduct treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-17 08:16:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>Three doctors provided evaluation through using BPRS and SANS. Two nurses provided assessment through using NOSIE.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 13:40:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 13:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wei-2005">
<DESCRIPTION>
<P>The designer of the trial provided evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 14:01:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-1999">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-16 14:13:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-09-17 18:51:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 17:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2003">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 17:33:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1999">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 12:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-1999">
<DESCRIPTION>
<P>Three patients could not comply morita therapy, another two were lost because of the family relatives did not collaborate after they were discharged.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 17:36:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lv-2002">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-17 18:49:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheng-2006">
<DESCRIPTION>
<P>Two patients leaving study early: one lost due to discharging from hospital (modified Morita therapy group), one discontinued because of relapse (standard care group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-17 07:57:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2002">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-17 08:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1994">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-17 08:16:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-17 08:18:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-17 18:51:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2005">
<DESCRIPTION>
<P>No direct description, judgement from tables in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 14:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-1999">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-16 14:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-07-19 13:47:49 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:30:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2003">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:33:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1999">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-1999">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:37:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lv-2002">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-19 13:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sheng-2006">
<DESCRIPTION>
<P>Only completed outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 07:56:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2002">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-1994">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:15:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2000">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-17 08:18:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 13:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2005">
<DESCRIPTION>
<P>They reported all the data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 17:26:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-1999">
<DESCRIPTION>
<P>Reported all data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 14:15:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-09-20 17:04:16 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2008-09-20 17:04:16 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2008-09-20 17:04:07 +0100" MODIFIED_BY="Grade Profiler">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Morita therapy for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B>people with schizophrenia</P>
<P>
<B>Settings:</B>Inpatient care</P>
<P>
<B>Intervention:</B>Morita therapy</P>
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Morita therapy</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Mental state: 1a. Overall no clinically important improvement (BPRS) - short term</B>
<BR/>25-30% change BPRS<SUP>1,2</SUP>
<BR/>(follow-up: 10 weeks<SUP>3</SUP>)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.36</B>
<BR/>(0.13 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>66<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>333 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>120 per 1000</B>
<BR/>(43 to 343)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Mental state: 1a. Overall no clinically important improvement (BPRS) - medium term</B>
<BR/>25-30% change BPRS<SUP>1,2</SUP>
<BR/>(follow-up: 5 months<SUP>6</SUP>)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.36</B>
<BR/>(0.14 to 0.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>76<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>368 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(52 to 328)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the<B>assumed risk</B>(e.g. the median control group risk across studies) is provided in footnotes. The<B>corresponding risk</B>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the<B>relative effect</B>of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Not pre-stated primary outcome of review, but as close as could be gleaned from data.</P>
<P>
<SUP>2</SUP>May not be important for many people.</P>
<P>
<SUP>3</SUP>Rating of effect after 10 weeks of treatment but no real treatment-free follow up period.</P>
<P>
<SUP>4</SUP>Randomisation stated but not described. Blinding attempted but not tested. In hospital setting.</P>
<P>
<SUP>5</SUP>Single very small positive trial undertaken by skilled Morita therapists.</P>
<P>
<SUP>6</SUP>Rating of effect undertaken after 5 months of treatment but no real treatment-free follow-up period.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-09-18 18:32:19 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-18 18:32:19 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Suggested design for future study</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Methods</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allocation: randomised, block, fully explicit description..<BR/>Blinding: single, tested.<BR/>Duration: 12-24 weeks treatment, and then follow up to at least 1 year.<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Diagnosis: schizophrenia (ICD).<BR/>N=300.*<BR/>Age: adults.<BR/>Sex: both.<BR/>History: non-acute phase.<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1. Morita therapy + standard care: 4 phases, a. bed phase + diary, 1 week; b. light work, discussion, reading, diary, 2 weeks; c. heavy work, diary, physical exercise, 2 weeks; d. social/communication skills, diary, 1 week; total 6 weeks. N=150.<BR/>2. Standard care: as before. N=150.<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>General: relapse, general impression of clinician (CGI), carer/other (CGI), compliance with treatment., healthy days,<BR/>Mental state: CGI.<BR/>Quality of life. CGI.<BR/>Family burden: CGI.<BR/>Social functioning: return to everyday living for 80% of time.*<BR/>Adverse events: any adverse event recorded.<BR/>Economic outcomes.</P>
</TD>
<TD VALIGN="TOP">
<P>* powered to be able to identify a difference of ~20% between groups for primary outcome with adequate degree of certainty.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-20 10:36:15 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-20 10:36:15 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>MORITA THERAPY + STANDARD CARE versus STANDARD CARE</NAME>
<DICH_OUTCOME CHI2="0.45785049968362357" CI_END="2.839732156316312" CI_START="0.3615007530880656" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0131955946789066" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.45327737930074785" LOG_CI_START="-0.4418907936345939" LOG_EFFECT_SIZE="0.005693292833076961" METHOD="MH" MODIFIED="2008-07-19 13:52:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7953881510177536" P_Q="0.5748025959900671" P_Z="0.9801101251516783" Q="0.31471286553105726" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="385" TOTAL_2="376" WEIGHT="100.0" Z="0.02493084370879851">
<NAME>Leaving the study early: 1. Any reason - by end of therapy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14253837799711472" CI_END="3.9577251226166243" CI_START="0.11326340433995785" DF="1" EFFECT_SIZE="0.6695262659741856" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.5974456276984984" LOG_CI_START="-0.9459103889938029" LOG_EFFECT_SIZE="-0.17423238064765229" MODIFIED="2008-07-19 13:52:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.705770572736811" P_Z="0.6581071132856124" STUDIES="6" TAU2="0.0" TOTAL_1="236" TOTAL_2="239" WEIGHT="33.64162975222704" Z="0.44252808466311844">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16095" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-1999" TOTAL_1="35" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.45289633526487" CI_START="0.06471278770685286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1890098911741465" LOG_CI_START="-1.1890098911741465" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-19 13:52:26 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.3968605915391563" STUDY_ID="STD-Sheng-2006" TOTAL_1="41" TOTAL_2="41" VAR="1.951219512195122" WEIGHT="14.170276979993186"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16096" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16097" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="16098" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Wu-1999" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="19.471352772233853"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16099" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhu-2002" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.429536110874856" CI_START="0.3527457415154469" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.6463582465309213" LOG_CI_START="-0.4525382205148086" LOG_EFFECT_SIZE="0.09691001300805642" NO="2" P_CHI2="1.0" P_Z="0.7295738195097559" STUDIES="4" TAU2="0.0" TOTAL_1="149" TOTAL_2="137" WEIGHT="66.35837024777295" Z="0.3456925032214058">
<NAME>medium term</NAME>
<DICH_DATA CI_END="4.429536110874856" CI_START="0.3527457415154469" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6463582465309213" LOG_CI_START="-0.4525382205148086" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="16100" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Lu-1999" TOTAL_1="60" TOTAL_2="60" VAR="0.4166666666666667" WEIGHT="66.35837024777295"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16101" O_E="0.0" SE="0.0" STUDY_ID="STD-Lv-2002" TOTAL_1="38" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16102" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-1994" TOTAL_1="30" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16103" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6466795441287254" CI_END="2.7435222252865104" CI_START="0.35268070963176107" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9836601879229202" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4383084827679987" LOG_CI_START="-0.45261829403137893" LOG_EFFECT_SIZE="-0.007154905631690107" METHOD="MH" MODIFIED="2008-07-19 13:55:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7542607515292757" P_Q="0.6259403794310692" P_Z="0.9748864377908333" Q="2.6049853815009616" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="287" TOTAL_2="287" WEIGHT="500.0" Z="0.03148038136483867">
<NAME>Leaving the study early: 2. Specific reasons - by end of therapy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04084933945385273" CI_END="2.8434715564188764" CI_START="0.06611119502503664" DF="1" EFFECT_SIZE="0.43357271894637556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.45384888831102405" LOG_CI_START="-1.1797249924671027" LOG_EFFECT_SIZE="-0.3629380520780394" MODIFIED="2008-07-19 13:55:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.839829117244157" P_Z="0.38380491225727953" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.00000000000003" Z="0.8709070572960457">
<NAME>discharge - short term</NAME>
<DICH_DATA CI_END="7.950938032119094" CI_START="0.013974591508858441" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9004183686742379" LOG_CI_START="-1.8546608781135625" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-07-19 13:55:16 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.618347187425374" STUDY_ID="STD-Sheng-2006" TOTAL_1="41" TOTAL_2="41" VAR="2.619047619047619" WEIGHT="35.15680264088659"/>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="16104" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Wu-1999" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="64.84319735911343"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.022569637689829" CI_START="0.013849815723520037" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.498447686259046" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.676934234730993">
<NAME>discharge - medium term</NAME>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="16105" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Lu-1999" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.869017391942697" CI_START="0.14558122988201952" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.8368946159855735" LOG_CI_START="-0.8368946159855735" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.0">
<NAME>discharge &amp; lost follow-up - medium term</NAME>
<DICH_DATA CI_END="6.869017391942697" CI_START="0.14558122988201952" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8368946159855735" LOG_CI_START="-0.8368946159855735" LOG_EFFECT_SIZE="0.0" ORDER="16106" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Lu-1999" TOTAL_1="60" TOTAL_2="60" VAR="0.9666666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.55844228907183" CI_START="0.12577132357972595" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="1.8546608781135627" LOG_CI_START="-0.9004183686742377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-07-19 13:55:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.49723397076143483" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="99.99999999999999" Z="0.6788483319304867">
<NAME>relapse - short term</NAME>
<DICH_DATA CI_END="71.55844228907183" CI_START="0.12577132357972595" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8546608781135627" LOG_CI_START="-0.9004183686742377" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68" O_E="0.0" SE="1.618347187425374" STUDY_ID="STD-Sheng-2006" TOTAL_1="41" TOTAL_2="41" VAR="2.619047619047619" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.031112609677777" CI_START="0.32107180779163014" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="1.4476403360997032" LOG_CI_START="-0.49339782666037824" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-07-19 13:54:42 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3352732432227016" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.9635467178856145">
<NAME>unco-operative - medium term</NAME>
<DICH_DATA CI_END="28.031112609677777" CI_START="0.32107180779163014" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4476403360997032" LOG_CI_START="-0.49339782666037824" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="16107" O_E="0.0" SE="1.140175425099138" STUDY_ID="STD-Lu-1999" TOTAL_1="60" TOTAL_2="60" VAR="1.3" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.505428860071931E-4" CI_END="0.7155744853762038" CI_START="0.18108817048905218" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3599751024799101" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.14534515309330423" LOG_CI_START="-0.742109918869414" LOG_EFFECT_SIZE="-0.4437275359813591" METHOD="MH" MODIFIED="2008-09-20 13:52:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.979651568926278" P_Q="0.9796521776117595" P_Z="0.003560502603663442" Q="6.505039585830742E-4" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="71" WEIGHT="99.99999999999999" Z="2.91468276730818">
<NAME>Mental state: 1a. Overall no clinically important improvement (BPRS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0264185454210561" CI_START="0.12882795770650643" DF="0" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.01132449030887039" LOG_CI_START="-0.8899898779693958" LOG_EFFECT_SIZE="-0.43933269383026263" NO="1" P_CHI2="1.0" P_Z="0.05604155404594277" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="43.83830544840336" Z="1.9107123717180865">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0264185454210561" CI_START="0.12882795770650643" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.01132449030887039" LOG_CI_START="-0.8899898779693958" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="16108" O_E="0.0" SE="0.5294365215047319" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" VAR="0.2803030303030304" WEIGHT="43.83830544840336"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.893300950235112" CI_START="0.14278616895525809" DF="0" EFFECT_SIZE="0.3571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.04900220403689057" LOG_CI_START="-0.8453138586475477" LOG_EFFECT_SIZE="-0.44715803134221915" NO="2" P_CHI2="1.0" P_Z="0.02772310711552533" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="56.161694551596625" Z="2.2011824936986253">
<NAME>medium term</NAME>
<DICH_DATA CI_END="0.893300950235112" CI_START="0.14278616895525809" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.04900220403689057" LOG_CI_START="-0.8453138586475477" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="16109" O_E="0.0" SE="0.467757407724563" STUDY_ID="STD-Lv-2002" TOTAL_1="38" TOTAL_2="38" VAR="0.21879699248120305" WEIGHT="56.161694551596625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="38.761513942719695" CI_END="-1.3145379488108402" CI_START="-8.446146058077247" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.880342003444044" ESTIMABLE="YES" I2="89.680485633479" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-07-20 17:40:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="7.803088541979974E-8" P_Q="0.8207052666765441" P_Z="0.00730726089384355" Q="0.05136476902308919" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="12.949213654432416" TOTALS="SUB" TOTAL_1="161" TOTAL_2="152" UNITS="" WEIGHT="200.0" Z="2.6825070622037623">
<NAME>Mental state: 1b. Overall average endpoint score (BPRS, high=poor)</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="32.93761760480911" CI_END="1.6230274866196757" CI_START="-10.281497588502038" DF="2" EFFECT_SIZE="-4.329235050941181" ESTIMABLE="YES" I2="93.92791541878856" ID="CMP-001.04.01" NO="1" P_CHI2="7.041929084294907E-8" P_Z="0.15400327977566336" STUDIES="3" TAU2="25.689781700607927" TOTAL_1="93" TOTAL_2="96" WEIGHT="100.0" Z="1.4255326822210737">
<NAME>short term</NAME>
<CONT_DATA CI_END="-7.8023214421646685" CI_START="-11.217678557835328" EFFECT_SIZE="-9.509999999999998" ESTIMABLE="YES" MEAN_1="26.21" MEAN_2="35.72" ORDER="12" SD_1="4.32" SD_2="2.93" SE="0.8712805803092711" STUDY_ID="STD-Chen-1999" TOTAL_1="35" TOTAL_2="38" WEIGHT="34.87066026159346"/>
<CONT_DATA CI_END="0.8132229435459113" CI_START="-4.213222943545903" EFFECT_SIZE="-1.6999999999999957" ESTIMABLE="YES" MEAN_1="30.6" MEAN_2="32.3" ORDER="10" SD_1="4.9" SD_2="5.5" SE="1.2822801660489116" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="33.741501241984594"/>
<CONT_DATA CI_END="2.366969197215945" CI_START="-5.166969197215942" EFFECT_SIZE="-1.3999999999999986" ESTIMABLE="YES" MEAN_1="26.16" MEAN_2="27.56" ORDER="8" SD_1="6.75" SD_2="6.84" SE="1.9219583762402348" STUDY_ID="STD-Wu-1999" TOTAL_1="25" TOTAL_2="25" WEIGHT="31.387838496421956"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.765748656239069" CI_END="-0.7354725760275356" CI_START="-9.642201554474152" DF="1" EFFECT_SIZE="-5.188837065250844" ESTIMABLE="YES" I2="82.65619853342187" ID="CMP-001.04.02" NO="2" P_CHI2="0.016341551377152208" P_Z="0.02239200371097057" STUDIES="2" TAU2="8.593599649122798" TOTAL_1="68" TOTAL_2="56" WEIGHT="100.0" Z="2.283651786003229">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.4791856193214561" CI_START="-5.919185619321453" EFFECT_SIZE="-2.719999999999999" ESTIMABLE="YES" MEAN_1="26.89" MEAN_2="29.61" ORDER="20" SD_1="7.48" SD_2="6.73" SE="1.6322675541776395" STUDY_ID="STD-Lv-2002" TOTAL_1="38" TOTAL_2="38" WEIGHT="45.858836288358624"/>
<CONT_DATA CI_END="-5.377619606955886" CI_START="-9.18238039304411" EFFECT_SIZE="-7.279999999999998" ESTIMABLE="YES" MEAN_1="24.6" MEAN_2="31.88" ORDER="40" SD_1="4.64" SD_2="2.01" SE="0.9706200767207184" STUDY_ID="STD-Wang-1994" TOTAL_1="30" TOTAL_2="18" WEIGHT="54.141163711641376"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8132229435459113" CI_START="-4.213222943545903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6999999999999957" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.18491810883215662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="1.3257633121147026">
<NAME>Mental state: 1c. Overall average endpoint score (BPRS, high=poor, category C studies removed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8132229435459113" CI_START="-4.213222943545903" EFFECT_SIZE="-1.6999999999999957" ESTIMABLE="YES" MEAN_1="30.6" MEAN_2="32.3" ORDER="10" SD_1="4.9" SD_2="5.5" SE="1.2822801660489116" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.06" MODIFIED="2008-09-20 13:33:15 +0100" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 1d. Overall average endpoint score change (BPRS, low=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="58" STUDY_ID="STD-Wu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>7.32</P>
</TD>
<TD>
<P>4.91</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>t=1.49, p&gt;0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>4.89</P>
</TD>
<TD>
<P>5.94</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.02134992252870293" CI_END="7.009186577471355" CI_START="1.0134626146136911" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.011324596042523" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.8838297263734569" P_Q="0.8838297263734569" P_Z="0.008727370896735202" Q="0.02134992252870293" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="106" UNITS="" WEIGHT="200.0" Z="2.6225529351407433">
<NAME>Mental state: 1e. Overall average percent change (BPRS, low=poor)</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Morita</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.249187924919539" CI_START="0.550812075080461" DF="0" EFFECT_SIZE="3.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.022471494705939028" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.2823023703245457">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.249187924919539" CI_START="0.5508120750804615" EFFECT_SIZE="3.9000000000000004" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="11.0" ORDER="16117" SD_1="11.0" SD_2="5.0" SE="1.7088007490635062" STUDY_ID="STD-Zhu-2002" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.18372719115445" CI_START="-2.263727191154448" DF="0" EFFECT_SIZE="4.460000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.19357069103633995" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="56" WEIGHT="99.99999999999999" Z="1.3000883472114457">
<NAME>medium term</NAME>
<CONT_DATA CI_END="11.18372719115445" CI_START="-2.263727191154448" EFFECT_SIZE="4.460000000000001" ESTIMABLE="YES" MEAN_1="41.71" MEAN_2="37.25" ORDER="16118" SD_1="19.02" SD_2="17.05" SE="3.4305360936172047" STUDY_ID="STD-Lu-1999" TOTAL_1="55" TOTAL_2="56" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.08" MODIFIED="2008-09-20 13:33:38 +0100" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 1f. Overall average percent change (BPRS, low=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="61" STUDY_ID="STD-Zhu-2002">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>11.0</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>t=2.34, p&lt;0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>11.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.06853208722177" CI_START="0.12375052330200503" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.028787568235342186" LOG_CI_START="-0.9074529558958674" LOG_EFFECT_SIZE="-0.43933269383026263" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.06585139877317284" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="1.8394338526145693">
<NAME>Mental state: 2a. Depressive symptoms - no clinically important improvement (HAMD) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.06853208722177" CI_START="0.12375052330200503" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.028787568235342186" LOG_CI_START="-0.9074529558958674" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="16120" O_E="0.0" SE="0.5499523183400107" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" VAR="0.3024475524475525" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.5356665899175375" CI_START="-5.644333410082462" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.59" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="6.146025240103877E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="3.4250870233456183">
<NAME>Mental state: 2b. Depression average endpoint score (HAMD, high=poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5356665899175375" CI_START="-5.644333410082462" EFFECT_SIZE="-3.59" ESTIMABLE="YES" MEAN_1="8.75" MEAN_2="12.34" ORDER="16121" SD_1="5.12" SD_2="5.56" SE="1.0481485508339858" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.4936319978444095" CI_END="1.1083431087983526" CI_START="0.3110495715656946" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5871538547429606" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="71.37649298446415" I2_Q="70.32294727149329" ID="CMP-001.11" LOG_CI_END="0.044674225366192165" LOG_CI_START="-0.507170392510615" LOG_EFFECT_SIZE="-0.23124808357221144" METHOD="MH" NO="11" P_CHI2="0.061605411432221535" P_Q="0.0664096856244174" P_Z="0.10045977020757697" Q="3.3696068445484" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5954041163107067" TOTALS="SUB" TOTAL_1="46" TOTAL_2="46" WEIGHT="200.0" Z="1.6426287422689805">
<NAME>Mental state: 3a. Negative symptoms no clincally important change (SANS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9282567330113038" CI_START="0.40976050712718637" DF="0" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.2851648564896628" LOG_CI_START="-0.38746990138442533" LOG_EFFECT_SIZE="-0.05115252244738131" NO="1" P_CHI2="1.0" P_Z="0.7656248198947095" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.29810264944414716">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.9282567330113038" CI_START="0.40976050712718637" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2851648564896628" LOG_CI_START="-0.38746990138442533" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="16122" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Wu-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7594967551396676" CI_START="0.08229133248700522" DF="0" EFFECT_SIZE="0.24999999999999994" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-0.11947407726919651" LOG_CI_START="-1.0846459053867283" LOG_EFFECT_SIZE="-0.6020599913279625" NO="2" P_CHI2="1.0" P_Z="0.014477447837932285" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="2.4451934156362665">
<NAME>medium term</NAME>
<DICH_DATA CI_END="0.7594967551396679" CI_START="0.08229133248700525" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.11947407726919639" LOG_CI_START="-1.0846459053867283" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="16123" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Wang-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.3214285714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="104.58586301794529" CI_END="-2.4257839269602615" CI_START="-9.667138217056277" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.0464610720082685" ESTIMABLE="YES" I2="96.17539131525486" I2_Q="66.48528974273967" ID="CMP-001.12" MODIFIED="2008-08-06 17:04:43 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.1102230246251565E-16" P_Q="0.08410363864513604" P_Z="0.001063740485174983" Q="2.9837644196353117" RANDOM="YES" SCALE="45.30885839369485" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="63.15646875934798" TOTALS="SUB" TOTAL_1="198" TOTAL_2="201" UNITS="" WEIGHT="200.0" Z="3.27310209121187">
<NAME>Mental state: 3b. Negative symptoms average endpoint score (SANS, high=poor)</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="98.53958461004918" CI_END="-4.320734730252775" CI_START="-21.56509875731515" DF="3" EFFECT_SIZE="-12.942916743783961" ESTIMABLE="YES" I2="96.95553821149956" ID="CMP-001.12.01" MODIFIED="2008-07-17 14:16:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0032595447260404696" STUDIES="4" TAU2="74.04874576321284" TOTAL_1="160" TOTAL_2="163" WEIGHT="100.00000000000001" Z="2.9421381539970257">
<NAME>short term</NAME>
<CONT_DATA CI_END="-14.566831835884622" CI_START="-20.813168164115375" EFFECT_SIZE="-17.689999999999998" ESTIMABLE="YES" MEAN_1="42.63" MEAN_2="60.32" ORDER="16124" SD_1="7.53" SD_2="5.91" SE="1.5934824255703306" STUDY_ID="STD-Chen-1999" TOTAL_1="35" TOTAL_2="38" WEIGHT="25.26840609809925"/>
<CONT_DATA CI_END="-15.967150474749332" CI_START="-22.132849525250677" EFFECT_SIZE="-19.050000000000004" ESTIMABLE="YES" MEAN_1="51.88" MEAN_2="70.93" MODIFIED="2008-07-17 14:16:48 +0100" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="4.86" SD_2="8.68" SE="1.5729113134566741" STUDY_ID="STD-Sheng-2006" TOTAL_1="40" TOTAL_2="40" WEIGHT="25.28991457753739"/>
<CONT_DATA CI_END="-5.467209520756263" CI_START="-16.532790479243737" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="37.9" MEAN_2="48.9" ORDER="16125" SD_1="14.9" SD_2="6.4" SE="2.8229041568547593" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="23.59562501029609"/>
<CONT_DATA CI_END="-2.3171018221739397" CI_START="-5.882898177826063" EFFECT_SIZE="-4.100000000000001" ESTIMABLE="YES" MEAN_1="26.84" MEAN_2="30.94" ORDER="16126" SD_1="4.15" SD_2="5.08" SE="0.9096586426533012" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" WEIGHT="25.846054314067285"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5805299184870498" CI_START="-8.55947008151295" DF="0" EFFECT_SIZE="-4.57" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="1.0" P_Z="0.024757271616198905" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="2.2451692145417015">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-0.5805299184870498" CI_START="-8.55947008151295" EFFECT_SIZE="-4.57" ESTIMABLE="YES" MEAN_1="29.61" MEAN_2="34.18" ORDER="16127" SD_1="6.73" SD_2="10.59" SE="2.0354813215862033" STUDY_ID="STD-Lv-2002" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.412523458958141" CI_END="-3.05212668706557" CI_START="-6.44606133223858" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.749094009652075" ESTIMABLE="YES" I2="81.52432950022741" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.01999287208579359" P_Q="1.0" P_Z="4.132111288414752E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="5.485110463957383">
<NAME>Mental state: 3c. Negative symptoms average endpoint score (SANS, high=poor, category C study removed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.412523458958141" CI_END="-3.05212668706557" CI_START="-6.44606133223858" DF="1" EFFECT_SIZE="-4.749094009652075" ESTIMABLE="YES" I2="81.52432950022741" ID="CMP-001.13.01" NO="1" P_CHI2="0.01999287208579359" P_Z="4.132111288414752E-8" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="5.485110463957383">
<NAME>short term</NAME>
<CONT_DATA CI_END="-5.467209520756263" CI_START="-16.532790479243737" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="37.9" MEAN_2="48.9" ORDER="16128" SD_1="14.9" SD_2="6.4" SE="2.8229041568547593" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="9.407159560174982"/>
<CONT_DATA CI_END="-2.3171018221739397" CI_START="-5.882898177826063" EFFECT_SIZE="-4.100000000000001" ESTIMABLE="YES" MEAN_1="26.84" MEAN_2="30.94" ORDER="16129" SD_1="4.15" SD_2="5.08" SE="0.9096586426533012" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" WEIGHT="90.59284043982503"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.14" NO="14" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3c. Negative symptoms average endpoint score (SANS, high=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="73" STUDY_ID="STD-Wu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>38.13</P>
</TD>
<TD>
<P>21.52</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>43.95</P>
</TD>
<TD>
<P>17.28</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.15" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3d. Negative symptoms average endpoint score (SANS, high=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="74" STUDY_ID="STD-Wu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>20.39</P>
</TD>
<TD>
<P>11.25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>t=2.29, p&lt;0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>12.91</P>
</TD>
<TD>
<P>10.57</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.16" MODIFIED="2008-07-17 14:31:49 +0100" MODIFIED_BY="[Empty name]" NO="16" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Mental state: 3e. Negative symptoms average percent (SANS, low=poor, data skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.16.01" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA ORDER="75" STUDY_ID="STD-Zhu-2002">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>32.6</P>
</TD>
<TD>
<P>45.7</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>t=11.6, p&lt;0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.16.02" MODIFIED="2008-07-17 14:31:49 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>medium term</NAME>
<OTHER_DATA MODIFIED="2008-07-17 14:31:49 +0100" MODIFIED_BY="[Empty name]" ORDER="76" STUDY_ID="STD-Lu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>49.27</P>
</TD>
<TD>
<P>20.01</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>p&lt;0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>35.54</P>
</TD>
<TD>
<P>19.82</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.17" MODIFIED="2008-10-20 10:36:15 +0100" MODIFIED_BY="[Empty name]" NO="17" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 3f. Insight symptoms average endpoint score (Insight scale, low=poor, data skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.17.01" MODIFIED="2008-10-20 10:36:15 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA MODIFIED="2008-10-20 10:36:15 +0100" MODIFIED_BY="[Empty name]" ORDER="77" STUDY_ID="STD-Sheng-2006">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>9.07</P>
</TD>
<TD>
<P>3.00</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>t=5.245, P&lt;0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>4.58</P>
</TD>
<TD>
<P>4.04</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.18" MODIFIED="2008-07-17 14:30:52 +0100" MODIFIED_BY="[Empty name]" NO="18" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life: 1. Overall average percent change (QOLS, low=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="78" STUDY_ID="STD-Zhu-2002">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>13.6</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>t=15.6, p&lt;0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P>6.0</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="9.411666909269918" CI_END="-7.20897490773538" CI_START="-10.69595140370159" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.952463155718485" ESTIMABLE="YES" I2="89.3748895956458" I2_Q="89.3748895956458" ID="CMP-001.19" MODIFIED="2008-07-17 14:30:51 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0021561051499117134" P_Q="0.0021561051499117134" P_Z="7.967466676593168E-24" Q="9.411666909269918" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="18.075892670940174" TOTALS="SUB" TOTAL_1="82" TOTAL_2="70" UNITS="" WEIGHT="200.0" Z="10.064022730539255">
<NAME>Social functioning: 1. Overall average endpoint score (ADL, high=poor)</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6055073461526681" CI_START="-7.674492653847333" DF="0" EFFECT_SIZE="-4.140000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="1.0" P_Z="0.021691160920847545" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="2.2957328507001926">
<NAME>short term</NAME>
<CONT_DATA CI_END="-0.6055073461526681" CI_START="-7.674492653847333" EFFECT_SIZE="-4.140000000000001" ESTIMABLE="YES" MEAN_1="21.84" MEAN_2="25.98" ORDER="16135" SD_1="8.75" SD_2="9.62" SE="1.8033457153942416" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.495694706876842" CI_START="-12.504305293123158" DF="0" EFFECT_SIZE="-10.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" NO="2" P_CHI2="1.0" P_Z="9.851722338857551E-25" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0" Z="10.267708172143221">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-8.495694706876842" CI_START="-12.504305293123158" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="27.1" ORDER="16136" SD_1="3.31" SD_2="3.5" SE="1.0226235323367485" STUDY_ID="STD-Wang-1994" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.20" MODIFIED="2008-08-07 10:42:52 +0100" MODIFIED_BY="[Empty name]" NO="20" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Social functioning: 2a. Overall average endpoint score (SDSS, high=poor, data skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.20.01" NO="1" STUDIES="1">
<NAME>short term</NAME>
<OTHER_DATA ORDER="81" STUDY_ID="STD-Wei-2005">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>4.05</P>
</TD>
<TD>
<P>2.73</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>5.97</P>
</TD>
<TD>
<P>3.06</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.20.02" MODIFIED="2008-08-07 10:42:52 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>medium term</NAME>
<OTHER_DATA MODIFIED="2008-08-07 10:42:52 +0100" MODIFIED_BY="[Empty name]" ORDER="82" STUDY_ID="STD-Wang-1994">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>8.17</P>
</TD>
<TD>
<P>4.32</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>t=5.988, p&lt;0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>14.10</P>
</TD>
<TD>
<P>1.36</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="23.0918080096883" CI_START="9.708191990311683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="16.39999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2008-07-17 14:30:49 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="1.5599628830580218E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="4.803396824882017">
<NAME>Social functioning: 2b. Overall average percent change (SDSS, low=poor) - medium term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Morita</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.0918080096883" CI_START="9.708191990311683" EFFECT_SIZE="16.39999999999999" ESTIMABLE="YES" MEAN_1="72.57" MEAN_2="56.17" ORDER="16139" SD_1="18.27" SD_2="17.69" SE="3.41425049769916" STUDY_ID="STD-Lu-1999" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-41.06411695305087" CI_START="-50.675883046949124" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-45.87" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2008-07-17 14:30:48 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="18.70697790449247">
<NAME>Social functioning: 2c. Overall average endpoint score (IPROS, high=poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Morita</GRAPH_LABEL_2>
<CONT_DATA CI_END="-41.06411695305087" CI_START="-50.675883046949124" EFFECT_SIZE="-45.87" ESTIMABLE="YES" MEAN_1="57.13" MEAN_2="103.0" MODIFIED="2008-07-17 14:26:49 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="11.62" SD_2="10.27" SE="2.4520262029595035" STUDY_ID="STD-Sheng-2006" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.23" MODIFIED="2008-07-19 18:04:25 +0100" MODIFIED_BY="[Empty name]" NO="23" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Social functioning: 2d. Overall average percent change (IPROS, low=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2008-07-19 18:04:25 +0100" MODIFIED_BY="[Empty name]" ORDER="85" STUDY_ID="STD-Zhu-2002">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>43.5</P>
</TD>
<TD>
<P>18.2</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>t=13.6, p&lt;0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>7.7</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="21.397292929814427" CI_START="9.002707070185608" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="15.200000000000017" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.24" MODIFIED="2008-07-17 14:30:47 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="1.5308034199855172E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="4.807171922063885">
<NAME>Behaviour: 1. Average overall endpoint score (NOSIE, high=poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.397292929814427" CI_START="9.002707070185608" EFFECT_SIZE="15.200000000000017" ESTIMABLE="YES" MEAN_1="143.9" MEAN_2="128.7" ORDER="16141" SD_1="14.3" SD_2="11.2" SE="3.1619422492953264" STUDY_ID="STD-Wang-2000" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.25" MODIFIED="2008-07-20 17:34:25 +0100" MODIFIED_BY="[Empty name]" NO="25" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Behaviour: 2. Average overall endpoint score (NOSIE, high=poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2008-07-20 17:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="87" STUDY_ID="STD-Wu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>5.26</P>
</TD>
<TD>
<P>6.38</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>8.95</P>
</TD>
<TD>
<P>6.59</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.26" MODIFIED="2008-07-19 07:20:58 +0100" MODIFIED_BY="[Empty name]" NO="26" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Behaviour: 3. Average change (NOSIE, high=good, data skewed) - short term</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2008-07-19 07:20:58 +0100" MODIFIED_BY="[Empty name]" ORDER="88" STUDY_ID="STD-Wu-1999">
<TR>
<TD>
<P>Morita therapy</P>
</TD>
<TD>
<P>7.26</P>
</TD>
<TD>
<P>6.23</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>t=2.52, p&lt;0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard care</P>
</TD>
<TD>
<P>3.60</P>
</TD>
<TD>
<P>2.76</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.23955483781952697" CI_END="2.285325637135204" CI_START="0.43117273811336054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.992658104507411" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.35894809164209224" LOG_CI_START="-0.36534870621932697" LOG_EFFECT_SIZE="-0.0032003072886173877" METHOD="MH" MODIFIED="2008-07-17 14:30:45 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.6245278461253634" P_Q="0.624744848040582" P_Z="0.9861811612193491" Q="0.23925484807769487" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="104" TOTAL_2="104" WEIGHT="200.0" Z="0.01732021194535556">
<NAME>Adverse events: 1. Specific problems - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3780431227466616" CI_START="0.30894892969915627" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.3762197257246891" LOG_CI_START="-0.5101133049859155" LOG_EFFECT_SIZE="-0.06694678963061322" NO="1" P_CHI2="1.0" P_Z="0.7671680318377949" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.29608125165183813">
<NAME>somnolence</NAME>
<DICH_DATA CI_END="2.3780431227466616" CI_START="0.30894892969915627" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3762197257246891" LOG_CI_START="-0.5101133049859155" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="16144" O_E="0.0" SE="0.5206364096586706" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" VAR="0.2710622710622711" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.6657424651268595" CI_START="0.31377666540972426" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.7532568298885784" LOG_CI_START="-0.5033793566719788" LOG_EFFECT_SIZE="0.12493873660829993" NO="2" P_CHI2="1.0" P_Z="0.6967350183549879" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.38973161308752957">
<NAME>postural hypotension</NAME>
<DICH_DATA CI_END="5.6657424651268595" CI_START="0.31377666540972426" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7532568298885784" LOG_CI_START="-0.5033793566719788" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="16145" O_E="0.0" SE="0.7381543164351169" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" VAR="0.5448717948717947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5430033861931511" CI_START="-0.9030033861931506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17999999999999972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2008-07-17 14:30:44 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.6255813256368681" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="0.4879555531195814">
<NAME>Adverse events: 2. Overall average endpoint score (TESS, high=poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5430033861931511" CI_START="-0.9030033861931506" EFFECT_SIZE="-0.17999999999999972" ESTIMABLE="YES" MEAN_1="2.87" MEAN_2="3.05" ORDER="16146" SD_1="1.82" SD_2="1.94" SE="0.36888605703783806" STUDY_ID="STD-Wei-2005" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>MORITA THERAPY + STANDARD CARE versus REHABILITATION + STANDARD CARE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.107558836724115" CI_START="0.47448260165981915" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.32377970766590874" LOG_CI_START="-0.32377970766590874" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="151" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early - by end of therapy - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16147" O_E="0.0" SE="0.0" STUDY_ID="STD-Cao-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.107558836724115" CI_START="0.47448260165981915" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.32377970766590874" LOG_CI_START="-0.32377970766590874" LOG_EFFECT_SIZE="0.0" ORDER="16148" O_E="0.0" SE="0.3803796060367126" STUDY_ID="STD-Tang-2002" TOTAL_1="91" TOTAL_2="91" VAR="0.1446886446886447" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5474209557288938" CI_START="0.5173472762254324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1896084739328506" LOG_CI_START="-0.28621783308196064" LOG_EFFECT_SIZE="-0.04830467957455503" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6906735723414144" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.39794114303952693">
<NAME>Mental state: 1a. Overall no clinically important improvement (BPRS) - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5474209557288938" CI_START="0.5173472762254324" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.1896084739328506" LOG_CI_START="-0.28621783308196064" LOG_EFFECT_SIZE="-0.04830467957455503" ORDER="16149" O_E="0.0" SE="0.2795027281187069" STUDY_ID="STD-Cao-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.0781217750257998" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.09193024929218E-5" CI_END="-4.641444634542692" CI_START="-9.255930630476595" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.948687632509643" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.99328080638069" P_Q="1.0" P_Z="3.573988965129313E-9" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="139" UNITS="" WEIGHT="100.0" Z="5.902792862103585">
<NAME>Mental state: 1b. Overall average endpoint score (BPRS, high = poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.4592780827470406" CI_START="-10.460721917252961" EFFECT_SIZE="-6.960000000000001" ESTIMABLE="YES" MEAN_1="33.44" MEAN_2="40.4" ORDER="16150" SD_1="7.81" SD_2="11.42" SE="1.786115431133535" STUDY_ID="STD-Cao-2003" TOTAL_1="60" TOTAL_2="60" WEIGHT="43.43816254820085"/>
<CONT_DATA CI_END="-3.8721679379201692" CI_START="-10.00783206207984" EFFECT_SIZE="-6.940000000000005" ESTIMABLE="YES" MEAN_1="33.44" MEAN_2="40.38" ORDER="16151" SD_1="7.8" SD_2="11.52" SE="1.5652492016580424" STUDY_ID="STD-Tang-2002" TOTAL_1="79" TOTAL_2="79" WEIGHT="56.56183745179914"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00226588485671874" CI_END="-0.9102257319741771" CI_START="-1.3184735449504148" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.114349638462296" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.962033999778211" P_Q="1.0" P_Z="1.0199714179096573E-26" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="139" UNITS="" WEIGHT="100.00000000000001" Z="10.699800896170169">
<NAME>Mental state: 2. Insight average endpoint score (clinician's judgement, high = poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Rehabilitation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8104952696235875" CI_START="-1.4295047303764128" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="3.04" ORDER="16152" SD_1="0.69" SD_2="1.01" SE="0.1579134784198824" STUDY_ID="STD-Cao-2003" TOTAL_1="60" TOTAL_2="60" WEIGHT="43.49638462295963"/>
<CONT_DATA CI_END="-0.838446282406186" CI_START="-1.3815537175938137" EFFECT_SIZE="-1.1099999999999999" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="3.03" ORDER="16153" SD_1="0.69" SD_2="1.02" SE="0.13855036099428095" STUDY_ID="STD-Tang-2002" TOTAL_1="79" TOTAL_2="79" WEIGHT="56.50361537704038"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.002997170141413137" CI_END="-14.946965057482021" CI_START="-21.32788325309974" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.13742415529088" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.9563405157397995" P_Q="1.0" P_Z="7.817396102135158E-29" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="139" UNITS="" WEIGHT="100.0" Z="11.142188953655932">
<NAME>Social functioning: Average overall endpoint score (IPROS, high = poor) - short term</NAME>
<GROUP_LABEL_1>Morita therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Rehabilitation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Morita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rehab</GRAPH_LABEL_2>
<CONT_DATA CI_END="-13.375354518252879" CI_START="-23.104645481747113" EFFECT_SIZE="-18.239999999999995" ESTIMABLE="YES" MEAN_1="23.67" MEAN_2="41.91" ORDER="16154" SD_1="8.96" SD_2="17.01" SE="2.4820075879550947" STUDY_ID="STD-Cao-2003" TOTAL_1="60" TOTAL_2="60" WEIGHT="43.01341960604655"/>
<CONT_DATA CI_END="-13.833636151792609" CI_START="-22.286363848207394" EFFECT_SIZE="-18.060000000000002" ESTIMABLE="YES" MEAN_1="23.65" MEAN_2="41.71" ORDER="16155" SD_1="8.87" SD_2="16.99" SE="2.1563477092152774" STUDY_ID="STD-Tang-2002" TOTAL_1="79" TOTAL_2="79" WEIGHT="56.986580393953446"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-10-16 15:02:20 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Details of search showing Chinese characters</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2008-10-16 15:00:27 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-05" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-06" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-07" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-08" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-09" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-10" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-11" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-12" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAGAAgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2nUtRurAxfZtGvtR353fZXhXy8YxnzZE657Z6HOOM+f6t8WAz2lppsCaZdtq7afcSa2IxFGsa5uGBSYDMe6Pqw3b8LuOcbPi3UtVTxt4S0Sw1SewttS+2faXhiiZ28qJXTBkRgOc9u/0rlNQ8MWPhbVbXxjpGqXurvYazI2riWaOaO1SVSt1L5cSqVkUFCQBwACVwOAD0zTvEuh6rM1vpetadfTqpdo7W6SVguQMkKScZIGfcVzGo+M9d1W01KPwboE13fadfyWUsl2IRAzxnDgfv0ccEENtPpjnIl+F1hc2/gS1vr+PbqOryy6ldvuB815WJV8Dhcp5fAxj0BzXntlNaadL4l1K/8I6Jq1rL4tubR72/cKbXey4aQmFwsIJGW3dX6eoB65oPimHXtW1XTP7PvbG70vyftEV15R/1qllwY3cHgZ69xWd418U3ugT6LYabLYpe6jdMHe9UmOG1jQvPMTvQfINpwWGRnHty3w3W8j8W65qln4YSz8P6slsbe4tD5cEZjiyCsciROyPvJ3hMbvUZYM8T6Jcx/Gfwvqd1Nb6jc3f237LbyxCKKFIId8KZw53B3ZjJzyQQo2gUAdFH4900eLbm1l17w6+hNarLBeJqUKuk27DRMpkJfI+YMAoHTk81Jr3j6HSdA0nW7GJLu01S9itYpbuR7NEVwxErF0JCfLnO3kHI4xnnZJ/EzfGSVodO0mPVf+EaKxpJfyvAq/aeHLCEMTu/gwMj+IVY+JNndan4e8H2PiK3tDNdeIrOC9itJXMThhIrbWIVgCD9RnGTjJAItE+JPiPxDpF3HY+H/M1x4vtlpFCgaG2gZsRJcNJLGRI4UsNvVGVwpGRXWeG/Fra5rN/pNxo99p9/p0UT3qTPC8cTyKGVFdHJfIyQdo4HODgVwNprWuad4esdIvtFu5NOXWl0fS55r+50u5eIgiB5AkQJTbwTxkgZTIyem+GV1e6j4Wk1jTtP06y0+9eea2sjLLLPJNu2tJPdMSWLOr/8syQu3k4xQAnjL4mDwnpBuL3w/qVndzo6WQuXtnV5QpI3LHOX2A43EDjI7kU7wb4/vfGul6fc6doM8mJVt9RupZo4YIXEYaQxjc8jckbRtGdwywwa81OvXA+KGuaDqV3BeT6lp40aSSe/DjzXKqEhlitP3eN5BTywu8MWJIFYugyXOrfEC903w3dJp+sKlva6dfLqTvEyWkYR0YpDtmSRYg/zKg+Qdc7WAPoDUPFqWnidfD1vpGo3+oGyF9ttvJVRFvKZJkkTncOnuPfGOfiMZdF1rULLwxq8yaO88N15klsipLCu51J84nA45VW9gelUJ01Sb42Q/Y57Kyvv+EXUzedC9zGP9J+ZVw0RPOMMccD7vPHOaXBrbeCPiS0eo6asCalqguUawctKwiG8o3nAICOgIfHctQB6Hc/EDSdN8K6Zr2reZaJf2YuoogpcFvJ83yhJgJvIyFDFdxHFZY8da34h8PWur+EfDF9dRyygqb17aNJo1crIoPn7o24OGKsOPukHI5rxRp91qfwS0G3i0WC9t4dGS8ku5bsxLZtFbAhgikNIzKZAo+6GwWBFM1HRtD8O/Aq21uz8P6PLqP8AZtq/2i7sknbzJjGGclwSSDISAcgYAxgYoA9NstYvry7jgn8N6nZxsTmeeS1KJgE8hJmbnpwD19OayJvHVppXiO40nxGbLR9+H0+eS+DrdR4YlmG0eTjAHz8M2QpbGTNonhDQ/Cmjajb29l58V15kt6z2yyPcA5JUxxoAVAJAjRcc4AyTnz3wfpkNlq/inxPoF3BpWiaZu0+FNRtLm4kt4olEtwBH5qlFLnfg5bJPCHIIB1Phv4mWV/d6smoahZOE1Waz02102CSeeeJAWEu1C7OpX+JVCjaeeQB1F54jtdPu5LWeLVHkTGTBpV1MnIB4dIyp69jx061538PbvWEjlCavptjceIr261i0tr3SJy8yFgCVPnKgOFDeWGchSG3EHI0fijq99eXOmeFbeHUbXT9R1K2stR1CNfKVkmJ/cxsw+clQSxXIGApzuK0AXfCnxCk1pNSvb+3uzYG9kj017HRbyQTW6sQJGdVYEnpjCkFTkc4GhrPjqHSvDz63c2Gq2Nq12bVJ7myJ8oElVuJItwcQ7h0O1zkAD5hXK6ums6d48+HtnFoumQfZYr6Gyt01OWRCi26rhnaAMuFAxw2e+OtbfjS71OHwbDp91L53iu+HlWMGk3M1tvnIILKQ24xxq25i52HaC23IAAOY0X41X954OvtT1DR7SG6iSZLWdLyFIp5kXdjypZVkwoeLIQuTuOMHArrvBPjk+MDBE0NnFILCK4m2ahC8jSnG8LAjOyxjI5cqwLAbc5I8S8LS+JINA0jRNN0bFp4h+2pJJaXEEc2qRom0qXlV/K8v5+yghjgbssfSfhq2sLruuWWqQ6mr+HrWzgstMOoI/loYpCFPl+XDKzDbhnHHy5ORmgDpT8QdGt/EE0EviDQ7rTJLV7i3+xSPLPEYkLyiQJvUrsBYHKHgqFbrWOnxgsINR8SXN1Ddz6Pp6Wb2clrp8wkkWZMkyF8KoyQVLbNw6buK5a5h8Za94n8b31xa2X2+00Yae+mKWcpb3ELyqkboDvmVguQQQ5ZgCo21ysWla/caF4t0uGw16S8Flo6TWiQ27EbY0wJUA8zAA+UINwA/ec5oA+ivE/iG38LeG9R1u6G6OziLiPkeY5OETIBxuYqM44zk8Vy0vjPXdFsvB974mh06xtNUeSPUpNjoLaRkL26AM2UJxhywIUg8gc1o+I/Csmq6xHq+p+I5rOx0zFxaQxRQrHbuqnfNKZVdXYZyrELsA45JavO9cv8AX9U+DranqesahNda3MILDSpbG3YOryYjQ4gDM5RWkV12ZO3aM4yAe2X1ybOwubndAohieTdcSeVGMAn53wdq8ctg4HODXmGnfFvUNZ1PRbe20WOCHUdSNskqrcXBuIEzvlizFEuwHGWLFkGSYzit2bwRd6d4PTRtLe114QtGLWHxOEmgtVXdkr5cW5jhtoBPAxggDafKLK9ufDmuXWu6NNa3t1azwy+Idat9QSe2ljuZFLR7Ps4Kgum7MQcoGYEsQAoB6J4Y+JGo+JtdsEW0gs9Ol0aXVJ4ljkuZyUuJIdqFcZztVsBCTyB1BG3p3xDsNf1G8g8O6ZqGsCzWF5bi0aBY8SpuXHmyoc8EEYyCpBxXD+EIPEF/8RNR1/QtN0WPRbS1GnW8KSSRWkkZYs/2aZYAHxMjlm2EfMQMghhg6TZxeGPF+r6JcaBo0lvc69pNm1nKr3cMEcsc5DI0uGMgU/eIxktgYwKAPVbXxdr2l6PPc+KfDM1t5MrD7VDc2cULRlsIzCS5/dscgFdzDPRjnATxL4um0e+0e0t4EinnRr/U1uUMn2KxiQtKz+UxIfPyofmUsCM9K47wdYWsF/4kOneB7TUbu28SXCWt04toorVVdMDecyIEGWASNu2Oc40PF3g+TWfGL7fDWqSaTceXLqlxZaiinUmjAEcRiedFWNe7bd2Rhdv3iANufjHHeXCJpL6OtlJex2jarcTTmO13lihliaKM5ZY5MbXKqR8zAcnpdD8ZyN4EufFOuJJDZxo08Re1W1aWIAbdqGaTJZshcsu7K4GCCfKfEhfT/iVr1lcah9r8zS2uNUitRcRJKyguQY3vUMm2E52q5UKSBHwSN7xVaSv+z7PPJKVsPKtZrCBUlieOMzKAJCbibepVgVUnC8cAgBQDpPBvjvW9b0XU5NT0qGDUdO+a5llYWtjD90mNpd8reYqEsw2DYflYKeTNoHxBv9UvvDEd74eWxh8QJcPbN9sZ5I1hQtlkMSjDDBUhjkNmvCLuynn1k2ml2iG4uNW1S1At9LubcrGyRqeEy+xVZm8kAlBuDBg+D6N8IpJrHV9TSWL93HftYpK2k3VzdFFVUWJrnYqxRpti+V1GMHKxjFAHUeIPiVcaN4p1fTYbORobLQ5r2Myadcljco5UZwAPIwP9ZgL/ALdNj+JuqCytf+JDBJP/AMI4NeufNvDCNgJDLGqpJ1wGXLDhgDgg1xnxNvrO68fagkyR+YvhmeBBfaTNMTMskjZi4XaQoYicZQAMeazYmXW7XWJrnw5Nc/8ACP8AhKLSwWFvIkcnlM4ugzSDC8Eo0Ycsp3AjIBAPXo/H9pFZeGJNS0+6iuPEFu9xBFYo92I1VFfDbVDk7WX7qHBz2G6mWnj23m8S39lmeeyt4oz5cOj3wuraRhnbKnlEFWHzK3ynttb71cla2v8Abuq/DLSra4nimtfDk1xdSW7+XJbwzWyQpIjH+LfwMZIIyRisxdS8W6LZWHi3VtIksr/RrK80jUrm5ZnF2qohtCQTuYPOwBeMnJBJYKcAA9F/4SzV28Ia7rE/h2fSpLK1lurNLuVH85BGXQuiNujbj5kOMZwGJzjL/wCE88RWeheGtSu9B0yX+3JbW3hMOpyJiSdNysymA7V4OQGYj/a602w8MTeFPgVqWlXTObkaTdy3Cs5YRyPG7FF+ZgAucfLwSC2Msa4XUNP05fCHgGRfBflSS3+nCa68m0H28GM7kyJNx8zr+8Cg/wARBoA9NsfFGuP8Rm8OanYafbQf2QdQBtZ3mYt5wj5dkQAYzxt7A7ucDb1TxTo2kXMFleXmb64/1VpBE887jDHcIowz7cI3zYxx1rg/Ddpa2nxrljtPD39hofDpJtfLgTeftI+fELMvPA5Ofl6YxXn2ieMdb0LRbr4ipdCeXUtd+yajp0igxzRiHzIwjnLx7AzqOSMbOMLhgD3LVfHnhzRdTOnalqsdvch40fKOyRNJkoJJApSMkKxwxHAz05ql4z8Sapos+j6docMFxq2qXbIkEse7MEaFpXXLxruX5cBnGc49x5X450HVfC0XjK3axlvbPxZe27WVxbkFkuPPaXyGizuJI3gMuQcL3YhdfXPCuraJ4x8BLp16j6++kXGnRtM4FvbtDa7QyYjLEBpHf5g2TgfKOgB2dv8AEa3urCTWJNKu7Pw7bvJHdapdyIVDh1RRCsJkMwLtjcMKMHDEjFang7xHeeIDr/2yOFP7N1m50+HylI3Rx7dpbJOW5OSMD2rwu+8CXkll4mtLDTo9RGhWUOlwy2nm3Hn3BuklZ4lbd5biMsJEU4VmbHDGvYfhZ/zOv/Y133/slAHoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK+JvBWl+K7/TrrVGu2Fks6JDDOYlkWZAjhyuGxgdAwzkg5BxVP/hB0vZI7XULqA+H7eUS22iWNkttbEhnYecMsZeWU4BVCUyVOa7aigDlPDPhC28HpLa6bqGpNprO7xafPIkkUBZgfkOzeAOeCxHJJyTmqNp8M/D0OpX93drdakl3evfG0vZfMto5n3BmWEAIThsZYMQAMEV3NFAHG6L4Ht/DlwP7E1jV7LTtyMNN89JrdQDkqolRnQMSxbawJLdRgYk8Q+EJda8RaDq8Wrz2EmlG4wYIUd381AvBcMq4x3Vs57HmuuooA43/hA2/t/wDt3/hJtb/tP7L9j8/Zaf6nfv27fI2/e5zjPvTta8KS61baHFNqs8kml6pDqJnnhRnn8ssdhCBFX72MgduhPNdhRQByFr4VuLjxBba/r2qf2je2PmrZRQW4t4LYSIquQuWdmIU8s5HzcAYBrO8P/C/TPDl9Dc2eq6y4ispLARvLGo8h3aQruSNXB3sWDBgwOOccV6BRQB51c/C7TJ9bhltrqbT9ITS10ttOtF8vzohN5rB5cltr5w2MM2TluSDZPw00a51HWm1KGC607VPsfl2KwmIWn2eMxrsZWyMg/wAO3AyOQTXeUUAclc+BtLutdg1qS51RbiGwWwVYb+WLMYfeCzowkZsnks5B6kE81Vk+HXh02N/Yw/2rbR3/AJhuDFqt1+8eQYZ2UyFXY99wOccgiu3ooA47U/BcOqeHdK8MNeyDQrRIo7qAxgy3ccQXy0MgI2DcoLFVycYBXnLvG/hSXxnpcektq89hYvKrXkUUKP8AaIwwbblhlGBUEMDjrlW7dfRQAV59H8MNKj8Ny6J/amryRz6l/aU8s00cjzy4HyyboysiEqrFWU5IBNeg0UAcPqXw303VbAQ3ur69cXaXAuo7xtTkEkUocsHRB+6QjJUbYxgdMHmrni/wu3iaHSYl1KTT20/Uor9ZY41kYmMNwN3APzZyQw45BrrKKAOKuvA0l9qun6rceKNce+03zfskuy0Hl+Yu1+BBg5AxyDjtU9t4SazivJRrN7e6m/mvZ32pRxXD2EsilWaEBF2qflygO35cADJz11FAHm1n8LdOt4fCdncTpfWfh9LkSW93arIt204ySQThQrfMBhuwzkZrY8L+DIvDOua/qFvLapDqjwmO0tLMQR2yxhgAAGIJIbJOBk5OOcDsaKAOb0zwydL8XeIteF55v9s/Zv3Hl7fJ8mMp97J3ZznoMe9GmeGTpfi7xFrwvPN/tn7N+48vb5PkxlPvZO7Oc9Bj3rpKKAOZ8Q6BdeIWjsZdS+zaM2PtttDCVmul5zGZt/yxt8oYBdxAI3ANVLXvBw1fUvDzpqcllpOkXEdyumQW8YRpIs+UVbGUAzgryCMABTzXZ0UAYuraLaa5ZPYais727gh0huJId4IIKsY2UspBOVPB9K5g/Dayl1/V76a/u49M1FII30qy/wBGiKRQGEI7IdzJhiQqlR2IbAx6DRQBxOm+AYNC82LQdd1zTLJyNljHNFNDDjOdgnjkK5JZjg8k+wxVf4Y6e0Frbx61rEUVrepqKbTbszXajmd3aIu7kkk7iRzgAAAD0CigDgofh0bO0v7a08UeIrePUbt7y6MEtvG7TMQWYOsIZc7RwpA7YwTVnXvBFpq1kxjttJfVpECS6lqGkxXUr4Tbux8g38KRnKjGNuOnaUUAeV2nwes28Pw6Fq2pebpUP7yO2sbUW2642Opnldmkd5MOMAMqDYBtI4roLnwjca1oVzoviPW7vVLSW9E/ywRQM8ClWWByi8jcuSy7GPbA4rtKKAPP9P8Ahta2HjdPEMWpXTwLcXV6lk8aYW5uBtkbeADs2hQEIyCoO7qDueFvDR8N/wBs/wCl/aP7S1WfUf8AVbPK8zb8nU5xt68Zz0FdJRQByN34Mtbj+27gXBuNR1WI2z3F+pmWK2PBgRY2jKx4LdGBLHcxYise1+GaaV8OZvCej6xPZSXO43d4YVl+0F12SAo33VK8AKQRhTknO70aigDitP8AANrpU5nsNX1W3uha21kk/wC4leKCFNojTzImCqxw7ADlgDx0p2qeBH1r7F9v8Ua5N9iu47y3+S0XZMmdrcQDOMng5HtXZ0UAcjfeC7XVPD0uialqGp3ltNci6unnuAz3GHD+WTtxHHkL8sQTG3jGTm9r3hy28QyaYbuWdP7N1CK/h8lgN0kedobIOV5OQMH3roKKAOS0/wAKy2vjm+8U3erT3kk1qLK1geFEFvCX8wqWUDf83QkAgcEseacPAvhtfEb62ulRi9e4W6ciR/LaZQQshi3bC43MQ23ILE9TmurooAwbfw1pNvrMms/YxLqT8C5uJHneIfN8sZcny1+dvlTaOcYrM8U+EH8Ta3o1+usXWmnTUuU3WiKJXEyBDtdshCAOu0nnjacGuxooAx7HR7XSdEj0nS0+wWsURig+zgExZz8w3Agtk5ywOTyc5NZng3wu/hbTbyCa/k1G8vLyW+urloliDyyYyVQcKMKOMnnPQYA6uigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=</FILE>
</FIGURE>
<FIGURE FILENAME="Ma 2006.JPG" FILE_TYPE="JPG" ID="FIG-13" MODIFIED="2008-10-16 15:01:18 +0100" MODIFIED_BY="[Empty name]" NO="13" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Sheng 2006b.JPG" FILE_TYPE="JPG" ID="FIG-14" MODIFIED="2008-10-16 15:02:20 +0100" MODIFIED_BY="[Empty name]" NO="14" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAGQAzgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2W/137BdeR/Zep3PAPmW1vvTntnNcd4n+LFh4RvLRdR0PWkiugxEjxIn3cZCgt8xGRnp1HJ7X/F/xKsPBmu6Zpl7p93cfbkLB7YqWU7toG0kZyff868x+Olzd66NCaHR9VhSD7Ruee2KglhGcDBPZCf8AJwAXPF/jHxdc/FyDQfDGp3FoZIoIvIaFWCFk8xnZHBGQrZPf5cdq9g1jX9L8MaZHeazfR28BkSHzZAcM56YAz6E+wBPQV4z8P9Ks/HfxA8Q+IL251CznlYXWmtbztBI0BkkjLAjkgbAh7ZyKxdJ0WTx/8WL/AMP6hrGo3eiaZLcSKlxevOSiOIwVZjxuJU5Hb86APpaOVJ41kjdXRgGVlOQQehBriNK+J3hzX5b2yii1UzW7tFNAmnTTNgEqW/cq+Afcg10ugaBYeHdLi0vTEkS0hzsSSVpCuTkgFicDnpXi3wb/ALc/4SbxiNJWw8v7SnnG735B3y7du3/gWfwoAf8ADS98W+HvFN5b6zD4jPh7ypBCLrTrqfLbxsKgISpIyTwB1yM4r0Dwz8UtF8SeKLrw9FZ6hbXkMkixm4gID7M7sjrGeDwwHp14rf8A+Kw/6gf/AJGrw34c+efj/q/2oRi48++80RElN+85255xnOM0AfRsjeXGz7WbaCdqjJPsK51/GEcNu1xJomuJEiF2ZrPGABkk81s393DZWctxO5jhjQu77ScAew5P0HNeOfEjxBr2sWqQ3Rn8LeD7icWst5dQMbi5JDH/AFK/OqYQ8HbkdTztABzfxJ+K9nr99ozeGtV1e0it2l+1tbu0DMrFMYweSArdeOfc16vD8QINV8PSaj4d0XVNVO0rAFh2q7jjDMTx798eteKfFHw94a0Hw74SPhwCSC7iuJ2unUiW4BEW1myAQOuBgAZPHWu58ZWeoeBvFZfwPrVva3eqN58+hzuuJnZiN8QfjLEEbQQcgBc5CgA77wR4h8Q6zZyp4m8PTaVew4O8D9zMD/dBJKkdwSfXPYYHijx5rugfFTTvDdpZWt/bajbxPHHK5gaJ2d1J8wBvl+XJ+UnsPfR8Aa7441w3Nx4n0e0020jzHEiwSxTPICOdrsfkxnnuelcH8TbtbL49+EZ28vYsVqrGT7qqbiQE+2Ac59qAO98WeN9f8G6G2r6j4f02W3WRYyttq8jPlunDW4H61J4Z8X+JfFvh231vTvD+lw29xvEQudWkDfKxUkhbcjqp71gfHHVNPu/hvNFbX9rNJ9qhOyOZWOMnsDV/4P6nptp8K9FgudQtYpV8/ckkyqw/fyHkE0AYPwp+KPiHxj4iuNK1KCzdFt3uRNEpjZAGVcYyQwyw9D7mvaq+YP2cv+Shah/2CpP/AEbFXo/iXQ/FMPxk0LWNAt5Bps8MUGoyI4CMiu2/eM9kYbfcDHIoA2NK+M3gfVLMTtq4sn6NBeIUdfyyD+BNeUp49n0X4vuui+IxL4aubuN5VmmMkCRMA0uN33CDuxtx0A5HFXPgJDPdQ+LJrGOzXUGS3WFriItGgYykqQCDtOBwD2HpXq1zdeI9OMI1TxL4XsvO+WPzbCRd74yVXdcjPf8AwoAwvEvxp8KaL9lawlOsSSPiRbVsCJO7EkYJ9B9eR37W11SLxP4b/tDQL/al1E/2a58v7rglclWHZgQQR2ryoeKviXq/jmQeHRY6npFhIYJJ4YPItLnpu+Z3YlgePkY4xnGCc9l8StQ8VaX4Sh1Pw0XF7BOjXMEUInDRYO4YKEkA7eRt4yaAMX4Z+P8AxDquparo/i23ihurB44vNCbGMrMVEZA+Uk4JGMcAnkciT47atqGj+CLO40y9urGd9SjjaW2laNivlyHGVIOMgflVjTtQuPF3irSrO7s3s5NOsRqGrQJxtvJYxHEhIOVZU3uMnI+XuvHH/G3wvb6N4KtLqPVdYumOoInl32oS3CcxyHIViQG46+mfWgD0XRfElponw30XWPEus/8AHxbQySXVyRud5V37QFHOMkDAzhcnoTXQzanbRWH9pI8lxasiuj2kT3BdWxgqsYYsDkHIB456V59oPw98Nan4F0K/8QzX97ANLhm2XmpS+Rb5iVmKAMAgAH0AHtXS+G7TRf8AhE5LbwNqEUVvvLQyCZ7lI5OOCrsSFO3BUEcEkYJzQBPd+NtOtraa4FnrjCJGcqNFuwTgZxlogB+JA9SKp+B/iTo3jozw2EN1b3NugeSGdBjaTjIYEg8+uD7VzWufFCGDwz4i0fW4G0nxJb2ckaQkEx3DMuwSQsRyu45APOPXBxh/C+3g8OeCbC5n16PRbvXLqR4fOgVhKiYRVy3AOckcjIfv1oAk/aC1TUNKl8MyadfXVnITdHfbzNGcjyscqR6n869d0HefD2mtJK8rm1iLSSNuZzsGST3J9a8H/aBtNRtf+Ee+36p9u3fadmbdYtmPKz0654/Ku+8LeDNQ8Oxv4nh1/VNRmnslmn09kQrc7Y8pGM/dI4CkYx06ZFAHO/EDxENJ+NXhmabV57bSfscMspiuHWJlMsvJCnkHC57EDnimeK/G3iCP4sWelaJrN0dNvoYDHHZJBMZA4zujMvyc8HJIGK810vRNa1bxxoWkeKo7y1a8R4o1mj8uVIneXJCkZHzmQjI/TFO8L6VaQanrt5d6c+o2+hxM5/4mD2hYBygOURmLdMAFQNvOelAHq3jqfxXZ+BtSme58WR7YkEkkyaaseCwDZ8hvMAOf4c475Ga0vgXrOs654UvrvV9VnvhHeG3hE/zOgVFYkueWzvHXpt964i81XSdV8P6Dav4Oxb+I5mt7JhrsxkV0lWPLloz/ABEHnd9Kv/C7U9T8LfEC+8Bx2Vu9kbmSSRhOXeEhBlt5Vd+QqAjavqAOaAPRPitqF7pXw01e+0+6mtrqIwmOaFyjrmaMHBHqCR9DWH4R8aTQ/B5/EV9eNq99ZpNJcxmZQ6kSMERiBlcrtPIJwfTFee/EjxXNfeJvG2mWiO9kLK2hn4wBJDcRfOePV2TnrkewrBPhS/8A+EE0HV9O1A+ZrZOmjTowVe4b7RIeTnBX5VOT0OKAOr8ffEzV9e8FaVrOi2+saLGL1opbiK4CxSOEzsDKwZu/VQDg9wQPbNAvY28OaJLNd+ZNdWsOx5ZFLzuYt5wRwzEBmOOwJ6CvC/iT4K1Dwb8MtHspNcku7KO+Vfsht40RZWSRmcOBuPO4DcTw3bFdbZfDS98W+G/Dup6l4w1QyR6fBJbKiIvkbo1PBGCT0G4/McDJoA7zxN40sPCN7pMeqLIlrqErQ/agRsgYYxvyc4OTyOmOa8p8OfFu60hvEsvia6ub+3g1GOC1t4kjDIHaYuRwMgBBwTjtxmup+Kfg691bwhp9pH9s1T+z2eaW7kuIlnCgd12KsnGR1U/KPvEmvF/CWj614j8Q32taJ4fttYe2uBL9nvJEEKeYXK71Z13dDgA4yOfQgH0D4h8V3s/gjVr6w0PXIom06aSC9Bgi8vMZIk2mUSLt6/dzxkA8Vyfwr8YeJLzwJduNK1XXb2G6kjiuJbuAJkIhVGaSRXAGcnhuvXsLmsX7+IPBuovIvi+z1a7spA2mx2N00SylD+6z5O3aTgdRw3Uda4/wToVtYeAdQsvFtp4rtFa9MwsbeyuVSUBY9hyse3cXGBuYcqvTrQB7jod5qeoaVbzazpp0y9ORNbeckoBHdWUkEHr6j9a4nxBB4u0n4s6ZqFlqLDw7fGKG4jubsLAj8qUVGbh2AUrtAyxx6mt3wmY/E/hCG11TRdUsRbt5Jt9UMglO37rbyFLjBHPrkdsnyD4s/wBi33inS/CWiCC3ZZl+2XMszeXE7kKoYscDaCSf94DqCKAPfb7WNO067s7O9v7e2uL1iltHM4UzMCBtXPU5ZRjqc15Zqdzct+0rpdn9quFtjbFjEsrKpIgkIyAfUD61ynxq0VNB8O+D9NS8ub/ykus3NxKXaQnySSMk4HoBwB69abdW3hBPjdpsaWNoNBEA3wC2YxlhC+MpjJ+YKTkc9T3oA960vxPoesahPY6fq9rdXduW82GKUF1wcE46kAkDI45Fa800cEMk0rBI41LMx6AAZJr5w+GyWR+Omp/ZIEW2WS8NqI12LGu8hcKMYG3Ix2z7V2vxc8VPcxf8IRobpLquoFRdnzAiwRHBwzHAG4Y6n7v1FAGl4U+K+heONVm0OJb2wvJlkWAtj94oUklWH3WABPI7dT0pnwf1i7MGt+Hdbvr251zTb1xM13O8paPhVKlicDIPA9Qe9O+HvhLwz4D052TV7G61W5RRdXJnTAxzsj7hc/iSAT0AHC/FLU7Lw543t/FXhTX7RdYdAt5aQsHyAMbmxlSCNoKnngMO5AB9F1yPim/1rRtM1DWLfVdOgsrWBpfKuNOklckDpvWdRyeny9+9cd4M+N2neIbq20/UdNurXUpjtX7NGZ43PsB847noQADzXQePPB114wbyb3VRZaRbxmUW8fHnygEhpXI+VF9AD1JyDigDzGy+Lesa/pl9Pq3ifTfDqYEEcdlp7zTyFvvOoL5XAI+bPbgZHOrqXi3Xfhz4I0q903xJZ+JrK9lMdrNd2bKIkUHIBWTcxzx8x424rz+0stc8SaVDpFwlsvh/RJme91a0tQypGoAJ3IuZdo3EYyTuJJwNw9J17wxofxG8G6bpngHUNOS00qbdPHsdHClSoJXbuLnaeWxu5OaAM7VNQkuPj54fmkuJlS4t7ZmSJmQHKFgCA33dxzjJHXOe/wBAV8zJf2+q/H7w+LNbjFp5NrIs8JicPEhDZU9Oleq+PvDfiXU/EvhzVPDNytrLZu63crTFAYy0ZAK/xrw+R70AL4Y+K2g+KLSSW2g1aOeEgTQx6fNclM5wcwqwwcHGcdDxXJ6nf+IoPi5Z6vow8QDQ7kRG/RtLvPKAUbWBiMf3iqjBUcE/WsX4EzavdN4nnsGs2upZbV5TdKwU588kjb0Ofau78feN/E/gTRbfVLqy0i7iluRb7InlVgxVmB57fIf0oA1td8dCw06SfSfD2vardggR2y6VdQg+7M8QAA9snpx3FvTfEeoap4fi1ODw7e292z7JbC+/0eRMdSCw+YdMHjOfUYrE1Ky8f+JtDsJLLWNL0VpAlw7WyySMwIBVcsOnqMc9Omc9Dc3t/oPg2a/1i6hmvrKyklmmhj2o7KpOQpPfA47noB0oA4XSvitqnjOO80/wd4eZdSji3+dezqIohnGSO59B/QVh/Fm58SyfC6xPia0tbfUItWiAe1l3LIPJl+bH8Jz2/wD1Vyfh3/hJvB/wqvPE2l3VrYx6ndxQqWjLTuqFsFCTtAyXGNpJGeeldL8RP+Em1v4P6drWr3mnmB/s9yLWCyKsC4IVzIZCPusOigfMRgYoAv6ZqnjrQPAnhjVfDscuuWtzHi6sponnkRiThgwO4KeR6LtHXJr1nQte07xBpovtNuoLqHdsZoZAwRwBlT6EZH4EHvXm3w50A638K9LudR8T6vBZ+XNE9rBcRwQogkdcFgm/oM8t3x04qf4e3/wytPEdzY+FQ8OqFDb+ZLJIftSr8zFNzFT93PAB9BigBieN/G2t+NfEPhPSYtEhurIzPBdXAlG2IOFXONwLgSKemODxWl4E0fxZp0N5cTeM7PXYX3KsTlp0SYcH97uyuMY2jjk8A15tpd74xtfjX4huND0SGbUpnkt5orgM0UMZdSrlgVwPkU57gnA5FaOq6d4w8A+Pj4laSD+zHWO51N7VPs9q+fleMJk7nJHBxkswbAyaAOt8L/EbxH4n8XanoNrp2kJ/ZxkEt15sjRvtfYNuBznqPYGn/D7x14k1/wAba/oGsx2Bj055QZrZWUqyybNoyeV4YgkZ4568cp8NLlPBPh7U/HPiGzvEh1iYLF9ntyRGmS245PCuzYUn+6OfmFS/AtrvV/FHibxJKrrDdMd3Ta0ruZCOnUD0wPm6dMAHqXiLWfEGi6fqWowaXpk9jZW8lxvk1GRJWVELH5BARng8bvxFeaav8a9cXwbbaxa+H7a0W+lltobhr3zTG6AZYx+WPXjk/dOR0z1nxJ037B4Q8SavLrer+XJasi2YnVYFL4QADZnBLcgk5yenbwrxFolxpnwt8LXNxNesL24uZlhY/uox8oUgerAbgecgnpQB7Jfa943+HXgia/8AE0um6vPFPFFbyRO4Yq24Nv8AkUEjC4PU5OT6834+8ba8NX8F32lahcaUurWUUzwRS+Yi+YykZDDaxAOMlfUdKv8AxD+GMNn4X1G80OPWb/VLqeI3EfnvcNMN33iuMsR69ue2a5X4hQzWd38NrW5ieK4h021jlRxhkYFAQR2IIoA+mq8i+HnxH8T+NYL9V0bSGmsTHvdr2W3Uh9+ML5cp/gOckf4emajdnT9Kur0oXFvC8uwdW2qTjv6V87fDOwsTo15eWVp43maafy5Do8yRRrtGQpYSKXIDjkgdeAMmgDY8D+IPF978WfElkZ3u/Ia5b+z7vVZRbwYnVcI3lvnbuwPlXjnjGK6Kb4n+ILT4p2nhC50jTFieSKKUQ3TyMC6ht6yFV6BgdpTJweeQa8z8Hxlvifrym18VSY+0fu9Oudl6v79f9c28Z/2vmOWweetazvpOj/GjQrm407xLFNO0ZA1KZJZ3kYmOM8liUyAPvZwOPSgD6Wrn9Q182F1LANJ1W5KAfPb225G4zwcj1x9a0L+TUI7Ytp9tbXE+RhLi4aFcd/mVHP6VmNfeLUUs2iaEFAySdZlwB/4C0AfP3gXxT4ht/G+uTWFpq2q3AgneDTxcNsWTzAqtKu7BVQzDAzyRjHUbmnfGTxn4m8S6Za6Lo9q+I9txZ7wyzsOXk8w48sADjkgZ53ZAritOg8SQePNa03wrNFd6hfJLbyz2Ts6Ro0is+2RlXGCApfGOTg8g16x4I+HXiLwJYXjWdholzrM6sqajNfTYiXsoj8jpnk/MM+vAoA9ejLNGrOuxiASuc4PpmvHPiZ4ruPENl4Zs/BOuSmfU72SJJLG5aLJVVyrkEFceYpwexzjpXQ+C9F+I2i6k6+Itc03U9MlLO43yPNGxyRsJRQBkjgnAA4ArhfgLoGiazousy6ppNhfSJcoqNdW6SlRtJwNwOPwoA9Q8Ga5ptzZ/2GviWLWtZ09Nt7ISA7Nn5iBgblBYLkZ7AnNea/DC+8VeNPGWp60fEWowaJBdGZrQyF1fczMsKhiwRQOuO2AOxGTp2jSL8V/G+neHrC3W5FjNDZRgBEtzJJDGzj+6FWRzx2zgHpXpfgfwR4YtfDUEek6pdXkecz3NhrFxGks2BuJWKQKDjAxjOAM0Ad+sqPLIquGKNtYA52nAOD6cEH8azdR8Q2NjpesX0U8V22kwyS3MMMql0KIX2N/dJA714T8PFe0+Pur2lvcXKW6z3qGMzs3mKjsFDkkl8epJORmtjxr4Q8Uad428SeJtMW3TRrrS7hrhw67SotSrI8Z+8S67hwRyCT1oA7rRfip4Y8R6a8kKaixAVJ7ddNnnMZfgKxjRl+Y5A55rgPCi614W+KN59htddh8HO8riM6VdtHtZSyqkflZUhyBnA4U8nPNr4J2uoXPw4vF0m/isLj+2HMk0lsJ98Yhj+XBZcckHPOMHjmu11XU7jw9M0es+PrK0ZommjSWxjRmRTzjLfMfYcnsKAKmvfEXUrHVLSDR/COvapZHm6nGnTwlR6IGQEkdecDoM85Hd2F4t/ZRXSRTxJIgYJcRNFIvsysAQa8g8DyfFbVdcGuXF1Cmj3RVjFqK7FeHj5o4kyUbbyOQCepNdZ8TZfD2l+FrjWtW0+1u7mBRHZLcDO6Y5KADvg5J74De9AHLeFNc8Q6d8Ytd8ONPdXHh+JpZZPtchIskI3owZuQpJCgZ6HPbNaXxL8dWc/wALZ9T8NawxNxeR2kdzayOjo4PmMMjBU7VPXHB9xXM6V4fvdY8HJrN94U0GHU2XzrO1jR4JtRiUHeCiEEEqQQRndjDDa2Ti6YPC3jbVtCSy0k6Dpkd+kF/bQzEmWeWOVoCDjBA8kjJAP7wjHcgHr3w7TW9N8CQ3fi3Up2uNjTSfbiFa2iGcb2IDZwNxLkkdOMV2ccqTxrJG6ujAMrKcgg9CDXz14/t9Wn+IemeAofEmrXOn3ywC7+1yqTlnYn7qqCAoUgY6ivb/AA94fsvC+jDTrKa4a1iJZPtMxk8sYHAJ6LxnHuaAKnjfxdZeCPDx1e9ikmUyrDHFGQGkdsnAJ6YAY/hXG+KvE7eOPhPf6/4S1HULOawl82Ty3aCVdgBkRip5AR93BI4Hfpyuvl/i34wgSO/Sw8IacxjF1NIsfnt/G0atjLHgDghQMnBO0+vWEnhfTtDh0a2u9OGnww+SIGnRlKYwQ2TznnOeuTnrQBP4T1ez13wppWqWbyNbzQLtMjl3BHysrMeWYMCCe5Ga6CvlvTPHP/Cr/GGpadoV5DrfhuSUukKynCc/wtg/MMYJGQwAPpj2bwr490b4iWl7Z6fHqtqwhImcoYjHnj5ZUJAbnI5B4JxwaAOI+JOq6jafG7wtaWmoXltDcpZxTJBOyB1a5cMCAcHIx19K63xv8TofDfh2HV9GNnqaLqZsblPMOFIjdmUMOjAqvYjB9wa8U8drZR/GCKwk1HVbmytLi3t5J57iSe4Vchn8tjluCzYA79OtaXjzQvBln8ObfVvB19cXFvNqkcMytcOU3CKUjdGwGGHYkZwx9aAPVbm8+JHinRbS88Pnw/pVrfWsc6PLcSzToHUMOfKCg4P90/WpvAOiePdBZ7XxPq9lqenlSY386WW4R89NzIMqc9ycYGKpaZ48Twl8NtBvdT0DVksIrC1iFzGbZlcmNQCB527B68qD6gVNpfi/xprev2Ooaf4Tf/hFbtE2S3FxFHcbWP8Artu/pjkLg5HIPNAHptFFFAHz/wDHb/kofhH/AID/AOjRXqXijVtATTrjTdX1yGyFyBG8STATSISu5FUZY7lO35RnDZGDg1xHxH+G2u+OPHFnPDeRQ6UlsqNJLgmFtx3BUHLEjB5I9MjitjSPCui/DaNI9E8PajrWtPGP9IEXLbiRgytiOMZHIByBgkHqQDC+J93e+Arjw/4o8PJBBHDbyaa0Eke1PLZQ0a+Xw2BtY9eCq5HXK/ADQXg0DUPEFy7vcalP5aFjk7EJy2euS5bOf7o9asXfw113x9qa6p46v1treHcLTSrFwfKUkHDSEYycAEgEnjkYxXF2vh/4i/C/xWmn6ArX1hfzBYiYy1vKc8eYM/u2wOTkcA4JAoA+la+ffg9oOm6z4j8ZPf23nNBcxrGfMZdoZ5s9CM/dH5V7banUv7KQ3cdouoeWdyQuxh39sEgHHTtXz74C0D4jtrmuxaY40OG5uNmoXUkIYBlZuIg2SxG9sYIHTLDigD0C/wBP8P8Ahv4ipZatB5Wk6vaqbSaa6kCR3MbENGPmwNyspyccjHOa4rTk1P8A4WVc6t8M/C0D6ZFm1e5nyYLg5+eRXZvl56bD0AJB3Yr0/UvhlpWseGLnSNQv9QvrqYiQaheTmaVJAWKlQflVRuYbVABBPfmvN/tnxY+Gtv8AYY7FNa0u3TZby/Z2nWOMDj7hDqAB0bgflQB7dey6k2hyS2dvA+piLckMshEZkxyu4duozXzz8Y/Gms3jDwrrFrpizWk8d08thO8gDbGAU7gMHD56ele36Pf+J9U8HJfz2lnY6tdRh4IH3lIQ2MGTuWAOdvHPBI5I8q+KPw7t9A8Fpd2q3Oqa1e6ost5fvFulfMcpIAUfIm7BwO+M5wMAE/gBfFF1Y2WprrHhPWLGzskENtdzESadtRQDkRExsAg3c4OCc9DXAat8S77WfH+m+KnsLZbjTo1jjhjZtjqpdsknn+M+nAr0bTvhReamulXVpcPotpe6JbW2r4AMk/yRlkSMr+7JMY3MTyexywOdqvgOx0H4w+F9M0nSpn0s2ifaWKtIJCWlDs7dMlQM9BjsBQB3vhGDx7Prg1jVdb0S+0C+QyrDaO58tSuUMWYx7A5PQk9a4b4phJfj34OjdFZHFkrKwyCDdPkEV2Pgv4ea34L1+62+JJW8ObmNtYL8xbcej7hhcDHKYLH06HlfHfhnXdU+NujX2laXciGNrWQ3zwNJboUcsSxG0YAA+XcCfUZGADoPjjpen2nw3mltrC1hk+1QjfHCqnGT3Aq/8H9M027+Feiz3On2ssrefueSFWY/v5BySKt+LfA2veNNDOl6j4h0yK381ZS1tpLqxK5wMtcMMc+lT+G/CHiPwp4cttE0/wARaY1tbh9kk2kSNJ8zs5yRcAdWPagDxr9nL/koWof9gqT/ANGxV32reDPFXij4oXgvNW1O28JqkcipBdNGrnaP3aqMDO7cS2Dx3yRWL8H/AIf+J/C/jS9u9UsUtrNbWS1MrSK3mEujDYAc4+XOSMdR16egePrnUr7S5PC+g2pm1HVYjFJLICIbW3b5Xd2wRyMqAOecgHGCAcB+zbaypaeI7tl/cySW8at6sokJ/R1/OtT9oeNP+EK06XA3rqaKCcZwYpCeevYf5xXfeCfC9v4N8NW+j27eYyZeaXGPMkP3mx27AD0Arxv45eJtYuls/Deo6JHZILj7XDcRXfn+eAHQYG1dv3jkHnpQB6t8Koo4vhd4fjjUIptixA9WZiT+JJNbuv63aeHNBvNXvpESG2iL4Lbd7Y4Ue5OAPrWX8OrS4sfh9odtdxPHOlqpZHGGXPIBHY4I47VR+K9hJqPw41e2gsWvJ1RJI41BLAq6ksMc5C7j74I70Acv8OfDtn4y8OXfiLxDFPLd6rqE1yGiupYMIMIq/I43BSrAZ6ZxXD/EzSdOvvF1l4P8JWdzdX6sWuM3k04Dnov7xyF2rkse27qMEV1HhxvGdl8BJl0izurXU7a4dbVBBmaaBnDMyKRnOXfHGcLx2rA8C+FvihpFxdX+m6Zb2k1+VM11quDKRnJyCS45OTxk47kCgDttG8C+C7G1g8L6/qZvNXCBXim1CeDzgSdoji8wBlAGBgHpXbeGvA/h3whJcSaFp32RrkKsp8+STcFzj77HHU9K808f+BfG3ijwpFc6o2kXeo6ed8cOn2sglmDcMN7HtwcBRnHsM9F4Nj8dXvw1trW6k+waq0xh+034YzRW3Tfs28yDkANjPDE9iAcR8ZLo+Mddg0Hw/afbrvR4Jp76SFSTCMAlM9OAOQMncQo5yKqWMtz8UPhBD4c0+O2bXNCniaO2DiMzwBCgYFsDPzHPPVQTjcBXtnh3wnpvhXS3tLKJneY7rq4mO+W6c9WkY9Scn2GTXK+EvhVH4J8SaprWm6p5vn28sNtaywFFi3MrDcwb5gNoHQetAHk/xQ0fVdC8CeBtO1l83kCXu5N+/wAtS0RVN3fAIHHA6DgCvpfQf+Re0z/r0i/9AFfOfxem8Va34l0fRdU0WBbmFJHtv7PZ5luBIVBxkA8FOmAefcV9G6Xbva6TZW0uPMhgSNsHIyFANAHj3jr/AJOQ8H/9ekX/AKMmqPU/AcHgy717Wm8LHXtPdGlkmuNU8vZETvceUsWeD1JLcLnjkVZ8b2t2fj94Vu4rK6mgjtYg8kMLOF/eTZzgdgcn2rs9R8V6lfRSW/h/wrqOoSOu1Zr+H7HbYPBJ83DsBkHAXkZweuADyPx7e2nh7RdL/wCKI0S2+0nzbN/7Se6Xy+GYqqhNu7K/MD3455HefDHwRZRTR+MZtMv9M1K6QhLSa88+MRsBhxkbxkdnYkflXGp8FPFujPY6zp1/pdzqdpIZFs5IyYUwSwCFwQeSeCFweQc812HhO9+Kt/4g+x+IYLTT7GFlllmaFXMgH/LNCjbTnIye2PXggFv4v6dZW3w18R3cNnBFc3BtzNNHGqvKRPGBuYDJ49aj+FWnpc/DDw/dRJD9ut47tbW4miMghLzuCdoZSc4GcEHGRnmtn4s2N3qfw11izsbWe6uZPJ2QwRmR2xNGThRycAE/hWZ8OZL3wx8OdBsr/RdV+0YnLxR2xLR5mcgMpIK5DA8igDlPjpD4hi8I2D6lqOnXFn/aCjy7WxeBvM8t9pJaV8jAbjjqOvbW8L+DPE19p3hbXYvGklutvptt5Fmun/uxEYx8jfvAH4OCxGe4xxhvxfj1bxj4WtNM0jw9q73Ed8twxltwihQjr1z1y4/WrX/CR+L9B8IeH9N0Lwfe3d3a2kEN411HtRdkaqyrhskkg89Bjoc8AHQ/FTWpdE8BX/2Ysb6/K2FqiAlmeTghcc7tu8j3Ar528HaZ4oOk61feGn1OLU7C5tllt7N2VnjImLbkH3iGRflIPU8V9M6RFF4kisNc1bQJLHVLUOIoLpxIYGJALKAcZO0YYgNj0B589+BttPBr3jVpoJI1a7iClkIBIafOM/UfnQBxcM3iE/GOdbrTp7/WprG3+1WlrqhsCz/Zoix8xSOnJKjjrjgVf+KNnq0fhjfqPhS9soklTbez+JZb9UJ6r5Tt1OOuO1bTaJBrP7SWrJf6YL6zjtkd1mg8yIH7PGFJBBHXOM96o/Giz07R9JXTrLwTbWXn3CCDVbW3iVWwCSmVXcGP904zgkZxQB3ng2DWbv4R6JDo17Hb3k0Chrq5LSGJC53soOcsBnaDx0HAFeTat4J0rR/jDYeGrZGltLq38l3uv3rFpYnUyHoNwJ3DGMEA17r8OLSex+HehW1zC8MyWq7kddrLnJ5HbrXl/iW3mn/aW0nyY5H8tIXfYpO1QpyTjoPegDhPGnhLxJ4d0zw54fv2a+neS4e1htlaQKWMamNDjLH5QcDpurq7/X5T+0Fp+qNoOsK6W5UWBhT7Q2YJFyFD7cc5+90Br6MrxLUIpP8AhqHSpPLfatkzk7TgL5Eoz9M8fWgDC+HVpqEnxy1bUZtOu7aOWW8lIuISpjDvuAYjIBww7kc8E17Zp/hnSdMt7iC3sImF0/mXLyjzHuHzndIzZLHPPPTtW9XB+NNS8QX8U3h/wxptz9umASbUrhDDb2yNwSHYfO2P7gbHXqMUAeR+D9MsPF/x01C6itIX0y0nnuQgjBjZVOyM44xlirYx2+ppPjJo0V38VNE0jTYra3kvLSCBQFCIJHnkUFto9xnjOK9T8N+Bn+H/AIVuF8PRQX2tMgknkusj7SVH3FI+4Ou3r79cjifB/hrxP4z+JZ8a+J9KfTre1dXit54WjLOoxGFVucKQGLHv09gD1HS/BfhrRtaOq6Zo9raXph8nfCCqhOOiA7QeB82Mn15NU/EnhO71/UWmnuNNltQFEdreWdxOgxgklRcpGxyM52A44579vXL6z4c1DXbqRLrX7q20xhgWlhGsDuO4klO5mB5GF2cH1GaAPLNe8f65Za4ngrw5BoGtmZGtpILawe3iVjkNGMXBHAzk8AfnVbw3Y6h8IdTurDVdT0iwTULT7Wl/JaTXAlMQO6BcSRgMu4kcHduXuQBn3PhLxD4b+Mhk8HeHIxFbIHtBOztbiNofLZmdmB6lzjOcjjPf1DVPAOoeK9Cns/Fusx3Er/PAljarFFaSdmBbLvjkckAgnIzhgAef6Bpviv4m68PEd1dP4ZvbNVa2uLTSWWO4B4J8xnBc/KFKkkY49RXd+Kvh2ninUdKv9e1mSWysbUrfQRkwxXLKch8bsIOW3HOcAAEdRgeHdB+LGhazFo/9rWl1oqMCL65CzBEA4XYWWTJAAxnA7N3rsvHV5qzaF/YujRGfWtTQ26MqlY4EOBJM552qAeOSckYzg0AeLeBLBovgj451Exti4CQhyeG8sZ4Ht5nX/Ck1xVj/AGcvDknzZl1VyxZy3I+0KMZPAwo4HH5mvSNV0NtH+Fl94J0nR9TubgW5jE623yTSkhmbdnoTnHoMDtXEan4e8RX3we0LwtF4a1T+0rK+eebdEoTYTMRht3P+tXt6/iAdjd6R8Utb0XR103VdF0i3ghjdTbzzeZL8oxvJjIxj+HpnrnjHUa5o2ueI/ClhoupG1866niXVpLV2RBCpLvsz83zbVT/gZPQVVPiXVtO8Kwx6b4U1i41KK2jjjgliCIHCgfM27oPbr+tLoninxbeeF7yfUPCc1trUJWKCEMPKuHbgNy2URT97JPHQk8AA8c8QeDNTi+IkfgS2uAND1LUBqENrCwYW8fzAvgj5SqFxjvtGc8V654l+G9trOh6hZjVdZcPCwtrVr0+RGwGY12cBlDAEbiT7+jtK0uTwa0+s6xBf674l1U4uZNPtmkVFUZEaZwqIMAAsQWOPTAhvz8S/E0pjs47XwpYkYLyutzdOD6Bcqv5gj1oA+ebDVLCz8M3OjJ4fhuPEV1dGJbiWEvJHGQo2Kp6SbgQCBkZPfBr6P+Guj69pOiRp4iNgl9Ii7I7e2WOWNB/DIy4DkZXoOO5bPHnWsfCnxH4K1Ox8TeE7uTVbu1PmTx3Cgys/O5gv8SkEgjO4Z4J6jT8B+IfF/if4pfa/EmkzW6WthLFFH9meGO1ZimSA2Tubbjk559BigCX4ra/rPh74g+G30nUJbVp02yKvKSZcL86HhuD36cYwQDTPi7baj4esdP8AEV3qsWrSrcLaxWd3aIYEyruZRHnBf5QM+hqr8cdLv73xj4ae10ue+j27SkcRZXPmD5CcY5z39a0PHPw+vvEmhQ2mieCtJ0W5WdZnmjeBGKBWBQlFz1YHrj5aAK/jq81fUvg6NXuvFALXNpazS2UUMcfmGQplCR82BuJwOuOeK6f4LXt5f/D2CS5eDbHO8UKxW6xbUXAwduAx98A+uTzXHeLPC02nfCprQeBbGPUbe3toZNRthC8rOrRhnG0bzuIIPfk54zXY/BC1nsvhrBHdQSwObmZgsqFSRnrg/Q0AaHizwbe+N9UitdWu4YvDdrKkyWtsW866fac+axwEUE4AXJIJOQcYT4g+BtL8T+Flt5pJ7WPTIXltltioUFUwAQQcqMDgY+tbHiC5sblJNM1LQL3VLVgrMq2gliYg5HU9QRXM6jpPhifS7yG3+HjJO8LpGy6NEpDFSAQRyOe9AFP4X/EHWvH76lDqlhYRW9qi7pLYuhJfIVdrFs8K+TkY4471zd14G8Haj8TvssfjCRbi1lVxpkmXZXBBMaTO2Dz/AAAFhz6VS+FvhCTQf7WXxb4KnvPO8n7KJbBLjZjfvxu+7nK/XHtXS+INljd2jeGvhRa3ZU75pbjTYoSuOgTAznvntx17AHpev3Nnb6TLFeXKW8d4RaI7DI3yfIox9TXj3gay0vwfqx8Fal4i1VdemuAXh00uLZWZAy4O3JJTbliBjp0XNa/j7QPGnj5NAXToBpumErLcw3Dqs1tMCw3tg/MAMYC85PI9Od8WWfiXQfjlN4tsPDeo6raqEaIW8TssgNsIm+ZVbaQSeo7UAV/h1pCXXxi8UpJql1aSK90iATmO5lzMDk8YYYUk++DXR+MvCelWXjvQ/E+o+KmjtNPnjjn+1lpnWRG86NNyjCBgW+9jHGM7uOck1jVk8dv4zh+GHiAau8ZCKzymBGMfl79ggBJ29Ruxye/I6LwBo3iDxT4e8X2XjOwu7ZNXmEqPdQlH8wqQSqtzhNkW0HgYAHegD0nUvFujabp9tevdi4iu2CWq2Y897lvSNUyW/CvFfitrXjTU9BW+vLJtF8PyXYt4LN5MXVxlHIaUDOBhW+TI5I+9gNXpnww8CXvgPS7yzu9U+2C4kEiRohWOLAwSM85bjP8AuisD9oZHk8AWCopY/wBqR8KM/wDLKUfzIoAl+H+geGtP8GaZLaeI57OS7torm6jh1FVHnNGu/I7YIxjtiuA+Jrpb/EXw+th4lu7tgiDet35j27NIQSrDgEgjjHYZyK77w3Jqtt4W0e3b4avMYrSBDM81qjSEIBuKswYE9cHkd64L4mWOsX3ivQ57TwVPp1zGBshi8qXziHyMmIkD8fegD6UUFVAJLEDqepr5/wDgJ4e0vV9F1ma+tBLIlyiq29lONpOOCPWve5hIYZBEwEhU7SegOOK8k+Gfw48S+GbO7jvNck0xZZgxgsUglLgLjcWkjbbz2HoaAMr4c2Vvp37QPiu0tI/LgjtJtq7icZlhJ5PPUmrHhjwX4o0H4z6jfW0bW+gXE808sgwIpY33MiBAeSrMAPTBPTg7/hf4Z6jo3xJu/FOoa0l8ZUkA/chJGZsDLBQFHAPQelbnjfWPFWh2Et9oGlWWowxx5eJzJ5yn1Cr98DqQCD/OgDyT4e/8nJa//wBfeof+jGq74j+HOq3V/wCMtd8R3l0+lWsN1dabHJdbvNfYxj43EqqcAA4J47ZFaPwe8G+IbfXtR8YeILaSC5uhIiR3MWyZ3dwzyFSBt6EDpnJ7Yz2vjm21bxTEfCmlW80NvcMv9pahLEyxwxcNtjLACVm6fKSFxhsZ4AMP4AWc1t8NpZpVwl1fyzRHnlQqJ/6EjdK5b9pVFEnhmQD5mF0pPsPKx/M17TZ6YmheHotL0eJVFpb+XbJKx25A+XcRzyep+tfP/wAUY/GPirxRp2g3miRi4tdwhbTw8sUnm7SW3EDAG0ZyBjBNAH0jHEkEaxxoqIoCqqjAAHQAVy/iDwdbeI9Si1Ced2ubSIiwjmjWWC3lJyZTHxvJwBhjgY4weR2Fcn4m1LXo4V07w7Y+bqlyMC6uAVtrRefndsfMeOFAJ7kYwCAeAeK/EeveKPiRpul69dW+ly2F0LF5rGYokBZ8SSqzNwSMdT0UDrmvVPH/AIS03w98O9UvfD1qllfW09vfmdeXeSJxhixzyAzH6k+prC8QfBXS7PwPPNJfSvrwcTS6hMskgmcnlSiBmwSTggFiSM56VZt/C/jLxn4c0bw9qBm0Tw7aW0UdxLNgXV9tAGPLH3FGMAPz0YgngAGJ8KF1Dxt8StV8a6lFEGhhxuhXaiysojUKDnIEatnnPIz1r27WNFtNd0/7DqETy2xcM8SysiyY/hbaRuX/AGTwcDNeI33w78a/D/xFHe+Bbi4urO5ZImRyrMCT0lUgKV6/OAMZPTqfa9LfVLfSfN1+S0lu0DO39nwSBQo7KpLMx+nXOAPUAwPiQulaV8ONYmextAIrJ7e3BiUCMuNiheOMFgcD0rk/gj4RsYfBh1a+06GW71CVmSSeMMRCvyqADnAyHOcDOR1AFXvEug618T9TtLW6gn0rwlayiVzcKY7q7YAjiM8oOSBuAPJODwBp+M7rxT4U8OiPwjpNtdWqRrbRQwRO09sNpAZUGd4GB7jIyCATQB5T8KPDthr3xJ8Rw6lp9veWMMMy+VMgYK7TKAQOxwG5HSvcINO0L4d+Er59Mshb2Nsr3TQq7OXfA7sSSThQPwrlPg94CuvCOh3N7qsXlanflcxcFoYlztUnsSSSQP8AZ7ivVqAPkqHRNY0j4reFZteG3UdUvrbUZoyMMhkuSMN6H5c47Zx1FdV8XPBmi+DPB7DT5Lkz6pq6TyLMwYBUjm4XCgAAy98nnqcVf+KFjqc3xq8L3dhp89z5EVq/7uJmXKXEjHJA4wBk+g5rq9S8MXnxA8d2mo6vaS2egaOSLWGddsl7JuBZip5WPKr1AJAHrwAZXxI0+ax+AOn2dwNs9nb2Ucg5GGUKp4Iz1+n9K9G8Cf8AJPfDX/YKtf8A0Utcv8a7C61L4czw2VrNczC5hby4ULtjdjOBz3rd8BW1/aeBNEtdTikiu4bKON43ADIAMKCB0IAHv680AdXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-15 11:57:21 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-15 11:57:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-06 10:57:31 +0100" MODIFIED_BY="[Empty name]">Cochrane Schizophrenia Group trials register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-15 11:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>[((*Morita*) in title, abstract and index fields in REFERENCE) OR ((*Morita*) in interventions field in STUDY]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
<P>The Cochrane Schizophrenia Group trials register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected. This version was used for the July 2008 search.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>